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PREFACE 
 
In this dissertation, I describe a set of methods for quantifying cellular heterogeneity and characterizing 
cell subpopulations in cancer and the microenvironment. Together, these methods establish a workflow for 
identifying biologically and clinically relevant cell subpopulations, quantifying the extent of cellular heterogeneity 
in biological samples, and quantitatively describing the features that are specifically enriched on cell populations. 
The work described here that has been submitted to or published in peer reviewed scientific journals is inserted 
into the body of the dissertation in the same form in which it was submitted for publication (Chapters 2-4). Many 
talented colleagues and collaborators played a major role in the development and success of this work. My 
collaboration with Dr. Melissa Skala’s lab at Vanderbilt University, in which I worked closely with former graduate 
student Amy Shah, merits special mention here. The results of this collaboration are described in Appendix A. 
Chapter 1 introduces the central goals and hypotheses of this dissertation. The biological and clinical 
significance of cellular heterogeneity in cancer is briefly introduced, followed by a short introduction to flow and 
mass cytometry and single-cell data analysis tools. These tools are further discussed in the context of the 
modular workflow explained in Chapter 2, as the foundation for the cellular heterogeneity measure described in 
Chapter 3, and as a method for analyzing single-cell imaging data (Appendix A). Novel methodological 
approaches for standardizing and automating single-cell data analysis are introduced. These methods are 
developed throughout the following chapters of the thesis and further discussed in Chapter 5. Specific topics 
relevant to each chapter are included in that chapter’s preface.  
Chapter 2, entitled “Methods for discovery and characterization of cell subsets in high dimensional mass 
cytometry data,” describes a novel modular workflow that incorporates multiple computational tools, including 
biaxial gating, t-distributed stochastic neighbor embedding (tSNE), and spanning-tree progression analysis of 
density-normalized events (SPADE) analysis into a workflow that facilitates discovery of both abundant and rare 
cell populations in single-cell data. The phenotypic signatures of the identified cell populations are visualized in 
a clustered heatmap. This workflow is presented and demonstrated through a use case in which AML blast, non-
blast, and normal human bone marrow cell subpopulations were identified and characterized after multi-
dimensional mass cytometry analysis. This work provides a scalable and automated analysis pipeline that can 
iv 
 
be applied to multi-dimensional, single-cell datasets arising from experimental platforms including mass 
cytometry and multiplexed flow cytometry.  
Chapter 3, entitled “High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes 
in Persistent Cells during Induction Therapy,” describes a method for quantifying longitudinal, phenotypic 
heterogeneity of acute myeloid leukemia cell subpopulations over the course of treatment. The 27 antibodies 
measured on AML patient samples by mass cytometry were used for dimensionality reduction analysis (tSNE), 
and the cells were displayed in the resulting two-dimensional phenotypic space. The distances between AML 
and normal cell populations in this reduced-dimensional coordinate space were used as quantitative 
representations of immunophenotype difference. Persistent (i.e. therapy resistant) cells were found to be more 
phenotypically distinct from normal hematopoietic stem cells (HSCs) compared to non-persistent AML or normal 
cell subpopulations. This work provides a conceptual framework that can be expanded and developed into 
additional tools for quantifying cellular heterogeneity from single-cell data in disease and normal biological 
contexts.  
Chapter 4, entitled “Characterizing cell subsets in heterogeneous tissues using marker enrichment 
modeling,” describes a novel method termed Marker Enrichment Modeling (MEM) that automatically creates cell 
population labels that quantify population-specific feature enrichment. The concept and equation behind MEM 
analysis is introduced and demonstrated through several use cases, including analysis of normal human blood, 
bone marrow, and tonsil samples; murine myeloid cells; human glioblastoma samples; and human melanoma 
samples. A measure of population similarity is then proposed that calculates the pairwise difference between 
cell population MEM labels, enabling direct comparison of cell populations from different experiments, 
institutions, and platforms. MEM is therefore presented as a first step towards fully automated machine learning 
cell identity, a concept elaborated upon in Chapter 5. 
Chapter 5 discusses the findings and approaches described in Chapters 2-4 and elaborates on future 
directions of this work, specifically in terms of machine learning cell identity using MEM labels and adapting these 
analysis tools for clinical applications.  
Appendix A describes the application of tSNE analysis for visualizing the results of in vivo autofluorescence 
imaging. NAD(P)H and FAD, two cellular metabolites that are commonly dysregulated in cancer, were imaged 
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by optical metabolic imaging in squamous cell carcinoma tumors were implanted into mice and subsequently 
treated with common chemotherapeutic compounds. The optical metabolic imaging parameters were used in a 
tSNE analysis to visualize the individual cells in multi-parametric space. The analysis revealed that tumors 
treated with cetuximab or cisplatin displayed a greater degree of metabolic heterogeneity than the control group. 
This work therefore demonstrated that single-cell tools such as tSNE can be applied for data analysis in various 
experimental platforms. 
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CHAPTER 1 
 
 
INTRODUCTION 
Biological and clinical significance of cellular heterogeneity in cancer 
Tumors are composed of heterogeneous populations of cancer cells that undergo rounds of clonal 
selection and expansion in the presence of microenvironmental influences (Hanahan and Weinberg 2011). 
Mutations and genomic instability, combined with evolutionary pressure from surrounding stromal and immune 
cells, gives rise to multiple cancer cell populations with distinct phenotypes and functions. Genetic changes to 
oncogenes or tumor suppressor genes, considered “driver” mutations, enhance the cell’s proliferative potential 
and ability to avoid both internal and external death signals. Cancer cells can resist or adapt to chemotherapy 
by acquiring novel driver mutations or losing expression of drug-targeted proteins. Therapies targeted against 
specific mutations in cancers therefore frequently fail to cure the patient because the cells ultimately evade the 
therapy through clonal selection. 
Intratumoral heterogeneity is thus highly relevant to prognostic and therapeutic decisions in cancer. 
Clonal heterogeneity has been found to correlate with prognosis and therapy response in many types of cancer. 
For example, high clonal heterogeneity was found to correlate with increased risk of progression in esophageal 
cancer patients (Maley, Galipeau et al. 2006). The presence of subclonal driver mutations was also predictive of 
rapid progression in chronic lymphocytic leukemia (Landau, Carter et al. 2013). This correlation between high 
degrees of cellular heterogeneity and poor outcome has been noted across cancer types, including but not 
limited to head and neck squamous cell carcinoma (Mroz, Tward et al. 2013), endometrial cancer (Supernat, 
Lapinska-Szumczyk et al. 2014), and acute myeloid leukemia (Baer, Stewart et al. 2001, Patel, Gonen et al. 
2012).  
 The immune system, known to be composed of highly heterogeneous and plastic cell populations, also 
plays a major role in cancer promotion, therapy response, and patient outcomes. For example, a heterogeneous 
subset of myeloid cells termed myeloid derived suppressor cells (MDSCs) is expanded in many types of cancer. 
This immature cell subset secretes factors to promote a malignant microenvironment and alter the immune 
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response to cancer (Berraondo, Minute et al. 2016). Tumor infiltrating lymphocytes (TILs) have also been shown 
to be a highly heterogeneous subset of immune cells (Hadrup, Donia et al. 2013). As a mechanism of immune 
evasion, cancer cells can suppress the anti-cancer activity of TILs, and as a result immunotherapy fail (Smyth, 
Ngiow et al. 2016). Measuring heterogeneity of tumor-associated immune cells is therefore crucial to 
understanding the immune response to cancer and continuing to develop and improve immunotherapy for 
cancer. 
Single-cell versus aggregate analyses of human tissue 
Traditional analyses of cancer average the genetic, phenotypic, and functional features of all the cells in 
a tumor. Previous efforts to quantify tumor heterogeneity have focused on deep sequencing analysis and the 
inference of cell subsets based on varying allele frequencies (Zare, Wang et al. 2014). However, protein levels 
do not always correlate with transcript levels due to post-translational modification and regulatory degradation, 
making it beneficial to measure protein expression level and activation in order to gain a complete understanding 
of cellular phenotype and function (Vogel and Marcotte 2012). Going forward, a quantitative, single-cell approach 
to characterizing intratumoral heterogeneity will aid in the development of novel therapeutic strategies that 
address the high rates of therapy resistance and relapse that is likely caused by the presence of multiple cell 
subpopulations in a given patient’s cancer.  
In recent years, several new platforms have been developed for measuring features at the single-cell 
level. Mass cytometry (CyTOF) allows for more than 30 features to be measured simultaneously at the single-
cell level (Dalerba, Dylla et al. 2007, Prince, Sivanandan et al. 2007) (Figure 1-1A). Phospho-flow cytometry and 
multi-parametric immunophenotyping approaches have been successfully employed in the field of cancer, for 
example, to identify minimal residual disease in AML (Amir el, Davis et al. 2013), to find signaling node activation 
states in AML that predict response (Irish, Hovland et al. 2004), and to identify a negatively prognostic cell subset 
characterized by its altered signaling in follicular lymphoma (Irish, Myklebust et al. 2010) (Figure 1-1B). Other 
experimental platforms are also being developed for single-cell assays. Single-cell RNA sequencing is now being 
used for applications such as measuring cell-level genetic changes in glioblastoma cells (Patel, Tirosh et al. 
2014). Multiplexed imaging mass cytometry can now be used to assess protein changes at the single-cell level 
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in tissues while retaining information about tissue structure and cell localization (Giesen, Wang et al. 2014). As 
these tools become increasingly high-throughput, novel computational data analysis tools will be needed to parse 
the large datasets. 
Single-cell data analysis 
Flow cytometry experiments yield data in the form of flow cytometry standard (FCS) files, in which per-
cell feature expression is recorded in an n cells by m parameters matrix. The standard method for analyzing this 
data is biaxial gating, a method in which the analyst manually groups populations of cells based on their co-
expression of pairs of measured markers. However, the widespread use of multi-dimensional flow cytometry has 
driven the development of computational tools and algorithms to facilitate cell subset discovery in high-
dimensional datasets where pairwise biaxial analysis would be impractical or insufficient for identifying 
phenotypically distinct cell populations. Clustering tools like spanning-tree progression analysis of density-
normalized events (SPADE) are frequently used for analysis of high-dimensional flow cytometry data, for 
instance, to cluster and visualize immune cells along a hematopoietic development trajectory (Bendall, Simonds 
et al. 2011, Qiu, Simonds et al. 2011, Bendall, Davis et al. 2014). Dimensionality reduction tools have also been 
adapted for use with flow cytometry data, such as t-distributed stochastic neighbor embedding (tSNE). The tSNE 
algorithm has been used to identify subsets of immune cells and leukemic cells (Amir el, Davis et al. 2013), 
identify and characterize understudied populations of murine myeloid cells (Becher, Schlitzer et al. 2014), and 
characterize the diversity of tissue-specific T cells (Wong, Ong et al. 2016), among other applications. Both 
SPADE and tSNE are discussed in further detail in Chapter 2. Many other computational tools have been 
developed for use with single cells data, including  variance maximization (Newell, Sigal et al. 2012), mixture 
modeling (Pyne, Hu et al. 2009, Mosmann, Naim et al. 2014, Naim, Datta et al. 2014), spectral clustering (Zare, 
Shooshtari et al. 2010), and density-based automated gating (Qian, Wei et al. 2010) (Figure 1-1C).  
Once identified, populations of cells are typically compared univariately by quantifying differences in 
median expression levels of measured proteins or other cellular features. Statistical methods are sometimes 
applied for comparing flow cytometry distributions, including variations on area under the curve (AUC) analysis 
(Kim, Donnenberg et al. 2016), K-S statistic-based methods (Cox, Reeder et al. 1988), and z-score calculations. 
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However, many of these types of tools make assumptions about distribution shape; for example, z-score 
assumes a normal distribution, and flow cytometry parameters are rarely normally distributed. Distribution 
differences also do not necessarily reflect population-specific enrichment of the measured feature. These 
methods also fail to capture both intra-population and inter-population variance in a single value.  
While useful for population identification and univariate comparisons of distributions, the available 
analysis tools do not provide a quantification of marker enrichment, quantify cellular heterogeneity based on 
phenotypic differences, or provide adequate means by which populations can be registered and identified 
between samples in an unsupervised manner. 
Addressing the need for novel analysis methods 
This work describes novel workflows and tools to quantify cellular heterogeneity and determine population-
specific feature enrichment, while laying the groundwork for further work in machine learning applications to 
automate cell population discovery and characterization. Chapter 2 establishes a workflow for identifying both 
rare and abundant cell populations in multi-dimensional flow cytometry datasets. This modular workflow uses 
biaxial gating for quality control gating, viSNE for dimensionality reduction and major cell population gating, 
followed by SPADE analysis for automated clustering. The results are visualized as a hierarchically clustered 
heatmap to give a comprehensive, qualitative view of population-level phenotypic signatures.  In Chapter 3, a 
method is described for quantifying cellular heterogeneity based on multi-dimensional phenotypic distances 
within the tSNE reduced-dimension coordinate space. Using this method, the phenotypic differences that can be 
visualized and qualitatively interpreted using the workflow described in Chapter 1 can additionally be quantified, 
statistically analyzed, and correlated with clinical parameters. Finally, Chapter 4 describes a method for 
quantifying population-specific feature enrichment in the context of the sample, a set of samples, or compared 
to other specific cell subsets.  These tools and workflows for quantifying cellular heterogeneity are applied in the 
analysis of normal human immune cells, AML, and other types of cancer in Chapters 2-4. Together, the work 
presented here provides novel methods for quantifying cellular heterogeneity in normal human tissue 
development, cancer, and other diseases.  
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Figure 1-1. High dimensional phospho-flow and mass cytometry allows for identification and characterization of 
distinct cell subpopulations. A) Primary human tissue samples can be analyzed by high dimensional flow cytometry to 
measure clinically relevant markers and phosphorylation events. Stars represent different categories of markers that can 
be measured. B) Negative prognostic cell subsets in follicular lymphoma were deficient in signaling through BCR. The 
patient with a better outcome had a smaller proportion of LNP cells (left) compared to the patient with a worse outcome 
(right) (Irish, Myklebust et al. 2010). C) Biaxial gating, viSNE, and SPADE are three tools that can be used to identify 
populations of cells. Surface markers on three cell lines were measured by CyTOF. SPADE and viSNE were used for 
dimensionality reduction and subsequent gating. Raij and Ramos = Burkitt’s lymphoma cell lines, Kasumi = AML cell line. 
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METHODS FOR DISCOVERY AND CHARACTERIZATION OF CELL SUBSETS IN HIGH DIMENSIONAL 
MASS CYTOMETRY DATA 
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Preface 
The high dimensional data resulting from single-cell experimental technologies cannot be sufficiently 
interpreted using traditional gating strategies alone. I therefore sought to develop a computational data analysis 
workflow that would retain the benefits of biaxial gating and expert guided analysis while also automatically 
grouping phenotypically distinct cell subsets in high dimensional space. To achieve this goal, I combined manual 
gating, dimensionality reduction with viSNE, cluster analysis using SPADE, and clustered heatmaps in order to 
identify and visualize the phenotypic signatures of cell subpopulations from normal human bone marrow and 
AML patient blood. Workflows like the one presented here are essential to expedite and standardize clinical and 
basic biology studies that aims to identify and track relevant cell subpopulations between conditions, over time, 
and between patients. The work presented here describes the first step in my overall goal of standardizing the 
methods by which populations of cells are identified and then quantitatively labeled. 
Abstract 
The flood of high-dimensional data resulting from mass cytometry experiments that measure more than 40 
features of individual cells has stimulated creation of new single cell computational biology tools.  These tools 
draw on advances in the field of machine learning to capture multi-parametric relationships and reveal cells that 
are easily overlooked in traditional analysis.  Here, we introduce a workflow for high dimensional mass cytometry 
data that emphasizes unsupervised approaches and visualizes data in both single cell and population level 
views.  This workflow includes three central components that are common across mass cytometry analysis 
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approaches: 1) distinguishing initial populations, 2) revealing cell subsets, and 3) characterizing subset features.  
In the implementation described here, viSNE, SPADE, and heatmaps were used sequentially to comprehensively 
characterize and compare healthy and malignant human tissue samples.  The use of multiple methods helps 
provide a comprehensive view of results, and the largely unsupervised workflow facilitates automation and helps 
researchers avoid missing cell populations with unusual or unexpected phenotypes.  Together, these methods 
develop a framework for future machine learning of cell identity.   
Introduction 
High dimensional single cell biology 
Single cell biology is transforming our understanding of the biological mechanisms driving human diseases and 
healthy tissue development (Irish and Doxie 2014).  Mass cytometry is a recently developed technology that 
enables simultaneous detection of more than 40 features on individual cells (Bandura, Baranov et al. 2009, 
Ornatsky, Bandura et al. 2010).  High dimensional mass cytometry measurements are single cell, quantitative, 
and well-suited to unsupervised computational analysis.  New analysis tools have been created to take 
advantage of the massive amounts of data that result from high content single cell techniques like mass 
cytometry.  Variations of many of these tools have been developed and applied for gene expression analysis, a 
field facing similar problems with data dimensionality. These tools draw on advances in machine learning and 
statistics that are not yet widely applied in biological studies.  Many of these tools are complementary and 
address different aspects of data analysis, and it can be challenging for biologists to know when and how to use 
these tools to get the most out of their data. Advances have also been made in automating and standardizing 
the flow cytometry data analysis workflow (Pyne, Hu et al. 2009, Aghaeepour, Finak et al. 2013, Finak, Frelinger 
et al. 2014).  Here, we present a modular workflow focused on high dimensional single cell analysis that 
combines multiple tools to provide a comprehensive view of both cells and populations.  Rather than making the 
workflow fully automated, the goal here was to combine the complementary benefits of expert analysis and 
machine learning.  This approach maintains single cell views, provides automatic population assignment for each 
cell, and facilitates statistical comparison of the key cellular features that characterized each population.  This 
semi-supervised workflow facilitates comparison of populations discovered by different computational 
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approaches, in different clinical samples, or using different biological features (e.g. RNA expression, cell surface 
protein expression, and cell signaling).   
An advantage of traditional analysis in flow cytometry is the reliance on identification of known, prominent 
populations with strong supporting biology in the literature.  Given the typical panel size for fluorescent 
experiments, this type of supervised analysis is fast and usually adequate. Unfortunately, expert manual gating 
has been shown to be particularly prone to inter-operator variability (Maecker, Rinfret et al. 2005) and a tendency 
to overlook cell populations (Krutzik, Clutter et al. 2005, Amir el, Davis et al. 2013, Irish 2014).  Recent efforts 
have developed new tools for high dimensional cytometry data that bring in elements of machine learning and 
statistical analysis, including clustering (Sugar and Sealfon 2010, Bendall, Simonds et al. 2011, Qiu, Simonds et 
al. 2011, Bruggner, Bodenmiller et al. 2014), dimensionality reduction (Amir el, Davis et al. 2013), variance 
maximization (Newell, Sigal et al. 2012), mixture modeling (Pyne, Hu et al. 2009, Mosmann, Naim et al. 2014, 
Naim, Datta et al. 2014, Chen, Hasan et al. 2015), spectral clustering (Zare, Shooshtari et al. 2010), neural 
networks (Tong, Ball et al. 2015), and density-based automated gating (Qian, Wei et al. 2010).  Here, we highlight 
use of these tools in a sequential single cell bioinformatics workflow (Table 2-1).  In particular, different tools 
address aspects of data visualization, dimensionality reduction, population discovery, and feature comparison.  
It can be valuable to apply multiple tools in order to view data in different ways and fully extract biological meaning 
at the single cell level (Figure 2-1) and the population level (Figure 2- 2 and Figure 2-3).  After identifying cell 
subsets with the aid of computational tools, measured features, such as protein expression in the examples here, 
can be compared between and within the subsets.  Traditional statistics used include medians, variance, and 
fold changes.  Other statistical methods such as histogram statistics and probability binning have also been used 
to compare distributions in flow cytometry data (Bagwell, Hudson et al. 1979, Overton 1988, Roederer, Moore et 
al. 2001). 
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Table 2-1 – A modular machine learning workflow for semi-supervised high-dimensional single cell data analysis 
Analysis step Traditional  Additional methods§ Method here 
Data collection 
1) Panel design Human expert - - 
2) Data collection Human expert - - 
Data processing 
3) Cell event parsing Instrument software 
Bead normalization and 
event parsing (Finck, 
Simonds et al. 2013) 
- 
4) Scale transformation Human expert 
Logicle (Moore and Parks 
2012) 
- 
Distinguishing initial 
populations 
5) Live single cell 
gating Biaxial gating + 
human expert 
No event restriction, 
AutoGate (Meehan, Walther 
et al. 2014) 
viSNE + human expert 
(Figure 1)† 6) Focal population 
gating 
Revealing  
cell subsets 
7) Select features Human expert 
Statistical threshold (Irish, 
Hovland et al. 2004) 
Human expert† 
8) Reduce dimensions 
or transform data 
N/A 
Heat plots (Irish, Myklebust 
et al. 2010), SPADE (Qiu, 
Simonds et al. 2011), t-SNE 
(Geoffrey Hinton 2002), 
viSNE (Amir el, Davis et al. 
2013), ISOMAP 
(Tenenbaum, de Silva et al. 
2000), LLE (Roweis and Saul 
2000), PCA in R/flowCore 
(Hahne, LeMeur et al. 2009) 
SPADE†,  
viSNE 
9) Identify clusters of 
cells 
Human expert 
SPADE, k-medians, 
R/flowCore, flowSOM (Van 
Gassen, Callebaut et al. 
2015), Misty Mountain (Sugar 
and Sealfon 2010), JCM 
(Pyne, Lee et al. 2014), 
ACCSENSE (Shekhar, 
Brodin et al. 2014),  DensVM 
(Becher, Schlitzer et al. 
2014), AutoGate, Citrus 
(Bruggner, Bodenmiller et al. 
2014) 
SPADE (Figure 2)†, viSNE 
+ human expert (Figure 1) 
10) Cluster refinement Human expert Citrus, DensVM, R/flowCore - 
Characterizing cell 
subsets 
11) Feature 
comparison 
Select biaxial single 
cell views 
viSNE, SPADE, Heatmaps 
(Irish, Hovland et al. 2004, 
Kotecha, Krutzik et al. 2010), 
Histogram overlays (Irish, 
Hovland et al. 2004, Kotecha, 
Krutzik et al. 2010), Violin or 
box and whiskers plots 
(Hahne, LeMeur et al. 2009),  
Wanderlust (Bendall, Davis 
et al. 2014), Gemstone  
Heatmaps (Figure 3A)†, 
viSNE (Figure 1C), SPADE 
(Figure 2C) 
12) Model populations N/A 
Median (Irish, Hovland et al. 
2004), JCM, PCA 
- 
13) Learn cell identity Human expert - 
Human expert† 
(Figure 1B, Figure 2B, and 
Figure 3B) 
14) Statistical testing Prism, Excel R/flowCore - 
§Methods with broad application (e.g. R/flowCore) are listed minimally at select steps based on particular strengths or 
published applications. 
†Denotes the primary approach used at each step in the sequential analysis workflow shown here.   
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Overview of the analysis workflow 
The workflow presented here was applied to a CyTOF dataset from the analysis of healthy human bone marrow 
and a diagnostic sample of blood from a patient with acute myeloid leukemia (AML).  The annotated FCS files 
and a step-by-step guide are available online from Cytobank (www.cytobank.org/irishlab) (Kotecha, Krutzik et 
al. 2010) and FlowRepository (http://flowrepository.org/experiments/640) (Spidlen, Breuer et al. 2012). This 
workflow was developed for use with high-dimensional mass cytometry data. However, it can also be applied to 
fluorescent flow cytometry data.  The main steps presented consist of event restriction, population discovery, 
and population characterization.  Each of these aspects of data analysis can be achieved with a variety of 
techniques (Table 2-1), and some tools address multiple steps.  By sequentially combining three different 
techniques, this workflow draws on the strengths of specific tools, keeps biologists in touch with single cell views, 
and enables analysis of data from different studies and single cell platforms.   
In the case of the example dataset here, the overall biological goal was to identify and compare three 
populations of cells: leukemia cells (AML blasts) and non-malignant cells (non-blasts) in the blood of a leukemia 
patient, and bone marrow cells from a healthy donor.  In the analysis workflow, cell events were first manually 
gated based on event length and DNA content to include intact, single cells (Figure 2-1) (Bendall, Simonds et al. 
2011).  Next, visualization of stochastic neighbor embedding (viSNE) was used to identify and gate major subsets 
(Figure 2-1).  Gated cells from healthy bone marrow and AML were then analyzed by spanning-tree progression 
analysis of density-normalized events (SPADE) to discover and compare cell subsets (Figure 2-2).  Finally, the 
cell subsets identified by SPADE were further characterized using complete linkage hierarchical clustering and 
a heatmap in R (Figure 2-3).  The details of mass cytometry data collection and processing prior to initial cell 
selection (gating) are not covered in detail here.  These early steps include experiment design, collection of data 
at the instrument (and instrument setup), any normalization, and transformation of the data to an appropriate 
scale (Table 2-1).   
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Fig. 2-1. Distinguishing initial populations with viSNE analysis of per-cell protein expression and expert gating. 
Plots show the use of viSNE to obtain a comprehensive single cell view and to initially distinguish cancerous and non-
malignant cells in the blood of an AML patient.  A) Expert analysis of mass cytometry data identified intact single cells 
using event length and intercalator uptake.  Subsequent viSNE analysis arranged cells along unitless t-SNE axes 
according to per-cell expression of 27 proteins. Expression of CD45 protein is shown for each cell on a heat scale.  viSNE 
automatically arranged leukemia cells in one area of the map and facilitated selection of AML blast and non-blast cells by 
expert gating. Populations identified by viSNE and expert gating were subsequently analyzed by SPADE (Fig. 2-2). B) 
Human interpretation of population identities based on viSNE analysis is shown.  C) Plots show expression of the 27 
proteins, nucleic acid intercalator (NA), and density measured per cell. 
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Figure 2-2. Revealing cell subsets with SPADE analysis of population hierarchy, cell abundance, and median 
protein expression. Plots show the use of SPADE to reveal clusters of cell subsets in cell populations identified by 
expert analysis and viSNE (Fig. 1).  A) SPADE analysis identified distinct population clusters in each sample.  Cell 
abundance is represented by size and color of each circle representing a population of cells.  Phenotypically distinct cell 
subsets fell into different regions of the SPADE tree.  B) Human interpretation of population identities based on SPADE 
analysis is shown.  C) Plots show expression of the 27 proteins, nucleic acid interalator (NA), and density measured per 
cell.  
 
The initial event restriction step that begins the workflow focuses the analysis on populations of cells.  The goal 
at this step is to remove events that do not contribute useful information while making minimal changes to the 
data and not over-focusing.  Event restriction is traditionally performed using biaxial gating (Table 2-1), but given 
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the high dimensionality of mass cytometry data, use of viSNE (Figure 2-1) can simplify the process of 
distinguishing initial populations and avoid overlooking cells with unusual or unanticipated phenotypes.  The 
second step, cell subset identification, is also traditionally performed by expert gating (Table 2-1).  However, 
clustering tools such as SPADE (Qiu, Simonds et al. 2011) (Figure 2-2), Misty Mountain (Sugar and Sealfon 
2010), and Citrus (Bruggner, Bodenmiller et al. 2014), among others, can be used to automatically assign cells 
to groups or clusters in high dimensional data.  In the workflow here, the goal is to find all the phenotypic clusters 
of cells in healthy bone marrow, AML blasts, and non-blast cells from AML blood (Figure 2-2).  As the final step, 
characterization of discovered cell subsets takes place downstream of manual gating or automated discovery 
tool implementation, and generally consists of feature expression comparison with heatmaps, violin plots, and 
histogram overlays for visualization, as well as data modeling and other statistical analysis.  This workflow 
emphasizes integration of automated, unsupervised approaches with minimal human gating and processing.  
This type of semi-supervised cell population discovery and characterization can decrease human bias and 
variability and identify phenotypically unusual or rare cell subpopulations.  
Advantages of machine learning tools: dimensionality reduction, clustering, and modeling 
Not all tools perform the same analysis functions.  Three functions that are useful for high-content single cell 
analysis include dimensionality reduction, clustering of cells into populations, and modeling. SPADE and viSNE 
both include dimensionality reduction steps that project multi-dimensional data into a lower dimensional space 
for visualization and further interpretation.  These algorithms aim to preserve key high-dimensional phenotypic 
relationships between cells when visualizing and comparing them in 2D space.  Depending on the structure of 
the data, other dimensionality reduction tools might be used (Table 2-1).  Locally linear embedding (LLE) and 
isometric mapping (ISOMAP) are designed for the types of continuous phenotypic distributions seen in 
developmental progressions.  ISOMAP accounts for geodesic distance in addition to local linear distances 
between high dimensional data points in order to reduce the dimensions of continuous and non-linear data 
(Tenenbaum, de Silva et al. 2000, Becher, Schlitzer et al. 2014).  A similar principle is applied with LLE, where 
locally linear embedding of similar data points in high dimensional space is preserved while allowing for a non-
linear global embedding of the data during projection into low dimensional space (Roweis and Saul 2000). In 
contrast, multidimensional scaling (MDS) and principal component analysis (PCA) preserve linear, multi-
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dimensional variance.  One of the advantages of PCA and other techniques, such as joint clustering and 
modeling (Pyne, Lee et al. 2014), is the creation of a model that can be applied to newly analyzed samples.   In 
addition to the unsupervised tools discussed here, population analysis techniques that include some supervision 
can be particularly useful for mapping features across known developmental progressions (Inokuma, Maino et 
al. 2013, Bendall, Davis et al. 2014).   
Notably, dimensionality reduction alone does not assign cells to groups.  Here, dimensionality reduction with 
viSNE is used to aid expert interpretation of cluster identity.  In this example, cells are projected onto a biaxial 
plot space by viSNE and then gated.  Thus, viSNE is being used to see the phenotypic relationships of the cells 
according to all 27 protein features.  This can help researchers visualize high dimensional data without losing 
rare populations that are best observed in single cell views.  Following t-SNE or viSNE analysis, a human expert 
can look for cell clusters or major populations, as is the case here (Figure 2-1), or a computational tool can 
identify cell clusters (Table 2-1), as with t-SNE + DensVM analysis (Becher, Schlitzer et al. 2014).  As the 
workflow becomes increasingly unsupervised, it is especially important to include a single cell view early in the 
analysis so that expert can perform quality checks and get a sense of the overall biological results. 
Data collection, processing, and initial population identification 
Data collection  
In mass cytometry, as with fluorescent flow cytometry, single cell suspensions are stained with metal-conjugated 
antibodies specific to molecules of interest.  At the mass cytometer, cells are aerosolized and streamed single-
file into argon plasma where they are atomized and ionized. The resulting ion cloud passes through a quadrupole 
to exclude low mass ions and enrich for reporter ions whose abundance is proportional to cellular features.  
These reporter ions are quantified by time of flight mass spectrometry (Ornatsky, Baranov et al. 2006) and 
recorded in an IMD format file.  These data are typically parsed into single cell events and converted to a flow 
cytometry standard (FCS) file for analysis (Spidlen, Moore et al. 2010).  Many software programs can handle 
FCS files, including Cytobank (www.cytobank.org), FlowJo (www.FlowJo.com), R/Bioconductor, MATLAB, 
Cytoscape, and GenePattern (http://genepattern.broadinstitute.org/) (Spidlen, Barsky et al. 2013).  Text files 
containing the expression matrix (where rows are cells and features are columns, and there is a median intensity 
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value for each cell) can also be extracted directly from the IMD file from the cytometer or from the FCS file for 
manual analysis outside of flow cytometry analysis software.  In Cytobank, export of text files with intensity values 
is available from the FCS file details page.  An expression matrix can also be extracted from the FCS file in R 
and MATLAB using FCS file parsing functions.  In R, the package “flowCore” can be used to extract the intensity 
values from the FCS file using the exprs() function (Ellis B).  In MATLAB, the tool “FCS data reader” includes the 
function fca_readfcs() to extract the intensity values of FCS files (Balkay).  
Here, the healthy human bone marrow sample analyzed was obtained as a de-identified sample left over from 
diagnostic analysis of non-cancerous tissue in the Vanderbilt Immunopathology core.  Acute myeloid leukemia 
peripheral blood samples were collected from consented patients.  In all cases, samples are collected in 
accordance with the Declaration of Helsinki following protocols approved by Vanderbilt University Medical Center 
(VUMC) Institutional Review Board.  The patient blood sample evaluated here was collected at the time of 
diagnosis following initial evaluation and prior to any treatment. 
Data processing and scale transformation 
In order to prepare data for dimensionality reduction and analysis, initial processing steps aim to ensure the 
quality of cell events and perform appropriate scale transformations. Quality control varies by user and is 
especially important when conducting studies across time or using data from different instruments.  Data 
normalization using internal bead controls can be applied as part of this data processing (Finck, Simonds et al. 
2013).  In this case, the two samples were collected sequentially on the same instrument and no signal 
normalization was required.  Efforts are underway to facilitate comparison of data among groups and centers 
and to report elements of panel design, instrument settings, data processing, and normalization. MIFlowCyt is a 
data standard set by International Society for Advancement of Cytometry (ISAC) that specifies the minimum 
amount of information that must be included in an FCS file to ensure reproducibility and transparency (Lee, 
Spidlen et al. 2008). ISAC has also established a file format for classification results from flow cytometry data 
(CLR) (Spidlen, Bray et al. 2015) that handles cell classification from manual or automated identification and 
compliments the Gating-ML file format that was developed for sharing biaxial gate classifications (Spidlen, Leif 
et al. 2008). Additionally, there have been efforts to standardize and compare computational flow cytometry data 
analysis tools. The FlowCAP project compares automated tools for cytometry data analysis using standardized 
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datasets (Aghaeepour, Finak et al. 2013).  EuroFlow is a consortium of research groups that optimize flow 
cytometry protocols and analysis methods and set standards for the field of immunology and hematological 
studies (Kalina, Flores-Montero et al. 2012).  Reporting of optimized antibody panels has also been standardized 
in the form of Optimized Multicolor Immunofluorescence Panels (OMIPs) (Mahnke, Chattopadhyay et al. 2010). 
Cytobank (www.cytobank.org) and FlowRepository (www.flowrepository.org) provide online access to annotated 
cytometry data files, including mass cytometry datasets (Kotecha, Krutzik et al. 2010, Spidlen, Breuer et al. 
2012).   
Because cytometry data are log-normal, a log or log-like scale is typically used to visualize and interpret the 
data.  Commonly used scales include inverse hyperbolic sine (arcsinh), logarithmic, and logicle (also referred to 
as “bi-exponential”) scales (Herzenberg, Tung et al. 2006). Logicle or log-like scales more accurately represent 
the spread of data around 0 than logarithmic scales, given that modern cytometers can produce negative and 
zero values that cannot be transformed using logarithmic scales. The implementation of the arcsinh scale here 
was first used for fluorescent flow cytometry (Irish, Myklebust et al. 2010) and is now standard for mass 
cytometry.  Typically, a cofactor is included as part of the arcsinh scale transformation as a way of setting a 
channel specific minimum significance threshold.  The cofactor is set to an intensity value below which 
differences are not significant.  For mass cytometry, cofactors typically range from 3 to 15 and depend on 
background and signal to noise with the detection channel and antibody-metal conjugate.  In fluorescent flow 
cytometry, cofactors generally range from 25 to 2000 and are especially useful in correcting for channel specific 
differences in spreading of negative events that depend on fluorophore selection, compensation, and instrument 
setup. For fluorescent flow cytometry data, appropriate compensation must also be applied prior to analysis in 
order to correct for any spillover between channels. Algorithms have been developed for fluorescent cytometry 
to automatically determine scale transformations (Parks, Roederer et al. 2004, Moore and Parks 2012).  Applying 
an appropriate scale transformation prior to computational analysis is critical because it impacts quantification of 
distance between cells in the same way that it affects visualization of distance in biaxial plots.   
Initial population identification and quality assessment 
Beginning data analysis with a single cell view reveals the quality of the data and allows experts to spot rare cell 
subsets or artifacts that can be obscured in aggregate analysis.  It is valuable to review the single cell data to 
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verify computational analysis results, and it is vital in publications to provide representative single cell views of 
findings.  Here, intact single cells were gated by human analysis of event length and iridium intercalator uptake 
(Figure 2-1).  This initial gating might be accomplished various ways, such as use of cisplatin exclusion to identify 
live cells (Fienberg, Simonds et al. 2012).  Event length is generally higher for the mass cytometry equivalent of 
‘cell doublets’ that can occur when the signal from two cells is not well separated in time.  Intercalator uptake 
helps mark all cells and is proportional to nucleic acid content (Ornatsky, Baranov et al. 2006, Bendall, Simonds 
et al. 2011).  A biaxial view of each channel was then used to evaluate data quality prior to computational 
analysis.  If no intercalator positive events are seen in this view, it suggests that there were no cells in the sample 
or there was an error in DNA intercalator staining.  Once intact, single cells have been identified (Figure 2-1A), 
a quick check using traditional biaxial plots or histograms can be used to ensure there is no clear overstaining.  
Severe overstaining results in errors while collecting data on the cytometer because event length is too great 
and individual cell events cannot be distinguished.  Additionally, checks could be included at this step for 
contaminant signals.  Atomic mass contaminants, such as barium and lead, can be found in water, buffers or 
glassware.  Collecting data for the corresponding channels (137 and 138 for Ba, 208 and 209 for Pb) can be 
used to track these contaminants.  In summary, intact single cells are first gated by a human expert.  This step 
may be automated, but it represents an opportunity for quality assessment and initial familiarization with the data 
prior to computational analysis. 
Unsupervised machine learning tools 
viSNE 
viSNE is a cytometry analysis tool that employs t-stochastic neighbor embedding (t-SNE) in mapping individual 
cells in a two or three-dimensional map that is based on their high dimensional relationships (van der Maaten 
and Hinton 2008, Amir el, Davis et al. 2013).  viSNE can be used to provide a human readable two-dimensional 
(2D) view of cells that are arranged in a way that approximates high-dimensional phenotypic similarity.  viSNE 
is implemented in MATLAB and Cytobank (Kotecha, Krutzik et al. 2010), and the Cytobank implementation of 
viSNE is shown here (Figure 2-1).  viSNE can be run using a single population of cells or multiple populations 
drawn from one or more files.  However, cell features selected for analysis must have been measured on all cell 
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populations in a comparable way and features must be measured on comparable scales.  It is sometimes helpful 
to subsample cell events from populations to speed the analysis or test robustness.  Sampling can be ‘equal’ 
with respect to the starting populations, in order to ensure that each cell population is represented on the viSNE 
map by the same number of cells, or ‘proportional’, so that each population is represented by a number of cells 
proportional to its abundance.  When data are thought to contain rare cell subsets, subsampling should be 
avoided to preserve rare cells.  Initial gating can be used to focus the analysis on a population of interest and 
increase its relative abundance. Here, equal numbers of cells were selected from the AML PBMC and healthy 
marrow files for the viSNE analysis. 
The cell features selected for viSNE mapping affect the structure of the viSNE map.  Markers that vary highly 
between cell subsets will polarize subsets, placing them farther apart in tightly grouped islands.  Markers with 
low variance on subsets will cause those cells to be placed closer together on the map.  Thus, including markers 
that are not expressed on any cells can result in compression of islands on the map and loss of subset 
polarization.  Features that might contribute to clustering can be selected in an unsupervised manner based on 
variance.  For example, features that vary more in disease than in healthy controls might be particularly useful 
in stratifying cells associated with distinct molecular subgroups (Irish, Hovland et al. 2004).  Here, all 27 markers 
in the panel were included in viSNE mapping because all were expressed and variable on the cells in the 
samples. The displayed viSNE map shows cells from the AML patient file only (Figure 2-1).  The resulting viSNE 
map showed a broad distribution of heterogeneous CD45lo AML cells and several distinct islands of non-blast 
cells (Figure 2-1B). Relative protein expression as heat intensity can be viewed for each marker in the panel and 
are shown here for the 27 markers on the panel (Figure 2-1C).  The two main populations of AML blast and non-
blast cells were then manually gated from the viSNE map and exported as separate FCS files for further 
comparison to healthy bone marrow cells using SPADE and heatmaps. All healthy marrow cells were exported 
from the viSNE analysis as no additional gating was required to identify major populations. Depending on the 
sample and biological question, it may be useful to gate initial major populations from several or all files in this 
step of the analysis. 
The MATLAB implementation of viSNE can be accessed through the freely downloadable cyt tool 
(http://www.c2b2.columbia.edu/danapeerlab/html/cyt.html). Cyt employs a user interface that allows for selection 
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of features for mapping, selection of files or gates to be mapped, an interface for visualizing parameter intensity 
on a heat scale, and a tool within the interface for manually gating populations resulting viSNE map. 
SPADE 
SPADE is an algorithm that includes dimensionality reduction, clustering of cells into populations (also referred 
to as ‘nodes’), and visualization using a 2D minimum spanning tree.  Data must be appropriately scaled and 
intact cell events gated prior to SPADE analysis as described above.  Here, this is done prior to viSNE gating.  
SPADE has been implemented in Cytobank, R, Cytoscape (http://www.cytoscape.org/), and MATLAB. In R, the 
package “spade” includes functions to implement individual steps of SPADE and to execute a comprehensive 
SPADE analysis (Linderman M). CytoSPADE is a plugin available for use in Cytoscape that provides a user 
interface with the R implementation (http://www.cytospade.org ). The  MATLAB implementation of SPADE 
requires the SPADE V2.0 MATLAB tool that is freely downloadable 
(http://pengqiu.gatech.edu/software/SPADE/index.html). Here, the Cytobank implementation of SPADE was 
used to compare populations identified in viSNE guided gating.  User-defined parameters for SPADE analysis 
include downsampling, feature selection, and a target number of nodes.  Target downsampling, which can be 
indicated as either a percentage of cells or an absolute number, specifies how much weight to give clusters of 
varying density. A lower downsampling percentage increases the likelihood that sparse regions of density will 
be given their own clusters rather than being grouped into clusters with regions of higher density.  When a sample 
is thought to contain rare subsets of cells, entering a lower downsampling value can help distinguish these cells 
as a separate population (Bendall, Simonds et al. 2011, Qiu, Simonds et al. 2011).  Feature selection in SPADE 
can also be based on selecting highly variable or biologically relevant markers, as described above for viSNE. 
The number of nodes indicates the target number of clusters (i.e. cell subsets) that the algorithm should produce, 
and 200 nodes is a good default for standard mass cytometry datasets containing ~105 to 107 total intact single 
cells.  Including more nodes in the analysis helps to assign rare subsets to their own clusters.  These clusters 
can be easily combined in a process called “bubbling”, in which a human expert manually refines the cluster 
identity.  A table of basic statistics, such as median intensity of each feature, is generated for each population of 
cells identified by SPADE and can be downloaded as a text file.  Cell subsets identified by SPADE can 
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additionally be exported as individual FCS files for further analysis, as in the heatmap analysis shown here 
(Figure 2-3). 
In the example here, three populations were analyzed.  The two populations of AML blast and non-blast cells 
identified by viSNE (Figure 2-1) were compared with the population of healthy bone marrow cells stained with 
the same mass cytometry antibody panel.  Here, a concatenated file containing all three populations was also 
included to allow visualization of all cells simultaneously on one tree (Figure 2-2C). SPADE can initialize with a 
fixed or random seed and is random in the Cytobank implementation. The same random seed can be set from 
run to run in the MATLAB implementation. However, when new files are added to the analysis, a different tree 
can still stem from the same seed, which necessitates re-running the analysis to include any additional files. For 
this analysis, the downsampling percentage was set to 1%, the target number of nodes was 100, and the features 
used for clustering were all 27 measured markers in the panel.  The resulting SPADE trees are shown in Figure 
2-2.  
Including SPADE in this analysis workflow has several advantages. First, SPADE produces a visualization of 
population abundances by altering the sizes of each node depending on how many cells it encompasses. For 
example, it can be seen in the SPADE tree that the non-blast AML cells fall almost exclusively into one node, 
reflecting their relative homogeneity and the lack of normal immune cell populations in the AML patient’s blood 
(Figure 2-2). Clustering with SPADE also assigns each cell to a discrete group, which minimizes analysis 
variability and prevents loss of cells that are outside of gated regions in manual biaxial gating. In a standard 
SPADE analysis, the algorithm is asked to “over cluster”, producing hundreds of relatively small clusters rather 
than grouping cells into fewer, larger groups. This over clustering gives high resolution to improve rare subset 
identification and allows for a thorough annotation and characterization of all potentially discrete biological 
populations in the heatmap analysis. 
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Figure 2-3. Characterizing cell subsets with a heatmap analysis of median protein expression and hierarchical 
clustering of proteins and populations. 
A heatmap shows characterization of cell populations identified by SPADE (columns) according to median expression of 
27 proteins (rows).  For each sample analyzed in Fig. 2, cell populations identified by SPADE that contained at least 1% 
of total cells were included.  Cell populations and proteins were arranged according to complete linkage hierarchical 
clustering.  Heat intensity reflects the median expression of each protein for each cell population.  B) Each population 
contained cells from only the indicated source (healthy marrow, non-malignant cells in AML patient blood, and AML 
blasts).  Human interpretation of population identities based on clustered heatmap analysis is shown. 
Characterizing and visualizing populations 
Population heatmaps 
With some algorithms it is not straightforward to compare the results of an analysis of one set of samples with 
the results from another set of samples.  For example, with SPADE it is not straightforward to map a new sample 
onto an existing minimum spanning tree defined using different samples.  Instead, a new SPADE analysis is 
generally run that includes both the new and old samples.  In contrast, a heatmap can be used to compare 
populations identified in different analysis runs of SPADE or populations identified by different clustering 
techniques.  Heatmaps also provide a compact view that facilitates comparing many populations according to a 
large variety of measured features.  In heatmaps, different types of biological and clinical information can also 
be used to group populations or assessed for association with resulting groups (Irish, Hovland et al. 2004, Irish, 
Myklebust et al. 2010).  While population heatmaps provide an intuitive, high-level view of the results, they can 
obscure variation within subsets (Kotecha, Krutzik et al. 2010).  To address this, statistics other than median 
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expression can be shown in the heatmap, such as variance or the 95th percentile of expression (Kotecha, Flores 
et al. 2008, Irish and Doxie 2014).  
For the last step in the workflow here, tables of statistics for the hundreds of cell subsets identified in the three 
starting populations (Figure 2-2) were exported from SPADE as text files listing median expression of each 
feature for each cell subset.  Cell subsets were excluded from further analysis if they contained less than 1% of 
the cells in the starting population. This arbitrary threshold was set in order to exclude sparse clusters where low 
cell number could potentially increase the error of reported medians. Here, the 1% threshold resulted in exclusion 
of approximately 5% of the total cell events from heatmap characterization.  The table of statistics was then 
imported into R using the “read.table” function from the R.utils package (Bengtsson 2015) and visualized as a 
hierarchically clustered heatmap using the “heatmap.2” function in the gplots package (Figure 2-3A) (Gregory R. 
Warnes 2015). Output of a hierarchical dendrogram as part of the heatmap can be specified as one of the input 
parameters of the heatmap.2 function. The R package “stats” also offers a function called “heatmap” that 
performs the same function as heatmap.2 with slight differences in visualization options. After the clustered 
heatmap was generated, expert analysis was used to assign biological classifications to each group of 
populations in the hierarchical clustering, and included the same populations seen in viSNE (Figure 2-1B) and 
SPADE (Figure 2-2B): dendritic cells (DCs), monocytes, natural killer cells (NKs), CD8+ T cells, CD4+ T cells, B 
cells, immature myeloid cells (Imm. myel.), four subsets of AML blast cells (AML1 through AML4), and erythroid 
blast cells (Ery. bl.) (Figure 2-3B).  
Use of a clustered heatmap in the workflow allows for simultaneous visualization of several markers for the same 
clusters (population of cells) from multiple files.  Furthermore, nodes are hierarchically clustered, and this 
clustering can be pruned at various levels by the user to further group the nodes into biological populations. It is 
also important to note that the distance between nodes has quantitative meaning in the clustered heatmap 
dendrogram, as opposed to the distances on the SPADE tree that are for visualization purposes and not 
quantitative. Heatmap analysis therefore compliments the SPADE visualization by facilitating simultaneous 
visualization of nodes from multiple files and by quantifying phenotypic distances between the nodes. 
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Other packages and flowCore 
There are many R packages designed for statistical and visual analysis of flow cytometry data, including flowCore 
(Ellis B), flowViz (Ellis B), flowStats (Lo K 2009), and flowClust (Lo K 2009), among others. These packages 
include functions for producing heat maps, histograms, bar plots, biaxial density plots, and are part of efforts to 
automate and standardize computational analysis of cytometry data (Pyne, Hu et al. 2009, Aghaeepour, Finak 
et al. 2013).  Apart from the R packages designed for flow cytometry data analysis, other analysis and 
visualization packages can be applied to single cell data.  For example, box and whisker plots or violin plots can 
be produced to show median, range, and the distribution of the feature in each subset.   
Other Considerations for automated flow cytometry data analysis 
Algorithm Selection 
Three major considerations when choosing tools or algorithms for flow cytometry data analysis include 1) linear 
vs. non-linear measurement, 2) supervised or unsupervised approaches, and 3) need for modeling. The first 
consideration is whether a linear or non-linear method of dimensionality reduction is best for the data.  Phenotypic 
relationships between cells may follow a ‘creode’, or necessary path, that is non-linear with respect to protein 
expression (i.e. co-expression or co-variance of molecules is not linearly correlated with important progressions 
in cellular identity or trajectories in data space) (Irish 2014).  In this case, nonlinear dimensionality reduction tools 
may better preserve the high dimensional phenotypic relationships between cells compared to tools that assume 
a linear relationship between variables. The second consideration is whether an unsupervised or supervised 
method is needed.  In an exploratory analysis where novel populations are anticipated, unsupervised approaches 
will minimizes the risk of overlooking the populations. Lastly, a consideration is whether or not the goal of analysis 
is to build a model.  Mixture modeling tools can be implemented for analysis of flow cytometry data that will 
produce a model as output for downstream analysis. Additional issues to consider include 1) selection of 
features, which is generally initiated by hypotheses and pragmatic concerns and then narrowed to include those 
features with biologically meaningful variation (Irish, Hovland et al. 2004), and 2) aspects of statistical power, 
including sample size, cluster density, and false discovery rate (FDR).  It is vital to calculate FDR or a related 
statistic, such as the f-measure, in cases where a truth is known (Aghaeepour, Finak et al. 2013).   
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Scalability of Workflow 
Biomedical studies that employ flow and mass cytometry often accrue large numbers of samples over long 
periods of time. This and similar workflows can be adapted to accommodate data from these large studies. In 
order to account for experimental or instrument variability, normalization is necessary in these cases in order for 
compare samples run at different times or from different instruments. Bead normalization has been optimized for 
use with mass cytometry to control for machine variability between runs (Abdelrahman, Dai et al. 2009, 
Abdelrahman, Ornatsky et al. 2010, Finck, Simonds et al. 2013). Polystyrene beads embedded with heavy metal 
isotopes are run with every sample as a standard that can be used to correct MI values for each event based on 
technical variability. When samples accrue over a long period of time, a key consideration is that new results 
may not be easily mapped back to the original viSNE map or SPADE tree without re-analysis.  This is one 
advantage of heatmaps, which compare samples according to a simple ‘model’ of the data, such as median 
expression of selected features.   
This workflow as presented includes manual intervention that could be prohibitive when analyzing many data 
files simultaneously. While all steps of this analysis could generally be batched and automated, human review 
of single cell data is advantageous at workflow breakpoints to verify computational results and spot artifacts.  
Cytobank and other flow cytometry data analysis software allow for rapid, simultaneous viewing and pre-
processing of multiple files, including scale transformation and gating.  viSNE analysis can currently be run on 
up to 800,000 cells in Cytobank, and this limit is pragmatic, not theoretical.  Many files can be run simultaneously 
by subsampling cells equally or proportionally from each file prior to the viSNE run. SPADE can also be run on 
many files simultaneously, and data files with cluster information can be quickly downloaded in a compressed 
folder. 
Import of text files into R and selection of nodes based on the number of cells they contain can be automated 
and batched for highly scalable and rapid heatmap analysis. However, a potential limitation of large-scale 
analyses is the visualization of all nodes simultaneously on the heatmap. It may be useful in these cases to 
segment the SPADE tree into major populations by “bubbling” and then building separate heatmaps from each 
bubble rather than for the whole tree. Depending on the expected prevalence of rare cells in the dataset, the 
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user can request fewer nodes in the SPADE run in order to decrease the final number of clusters to be analyzed 
and visualized on the heatmap. 
Conclusions 
Data analysis in cytometry remains largely manual, supervised, and focused on large changes in magnitude of 
expression.  As new tools are developed to assist in gating, reduce dimensionality, and automate analysis, it is 
important to show biologists the value of these tools and to integrate them into workflows that can become 
routine.  The workflow presented here blends supervised and unsupervised analysis tools so that biologists can 
visualize results at the single cell level while still getting an accurate view of the big picture. Combining tools also 
allows the analyst to visualize data in multiple ways, which can be useful to extract the most meaning from a 
data set.   Existing tools allow for identification of populations based on single cell expression profiles and 
characterization of these subsets using standard statistics, including expression magnitude, marker variance, 
and subset abundance.  Going forward, tools that quantify cellular heterogeneity, identify critical population 
features, and assign biological identity to machine-identified subsets will be particularly useful in filling out the 
toolkit.   
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Preface 
Increased heterogeneity within tumors has been found to correlate with poor therapy response and poor 
outcome across a variety of cancers. However, these studies primarily focused on genomic alterations in 
aggregate tumor samples, and genetic mutations or other alterations do not always linearly correlate with altered 
protein expression levels. It would therefore be useful to develop metrics of cellular heterogeneity based on 
single-cell proteomic data, such as that generated from flow cytometry analysis.  In order to address this need, 
I worked closely with Dr. Brent Ferrell, then a medical fellow in Jonathan Irish’s lab at Vanderbilt University, on 
a project tracking phenotypic heterogeneity in acute myeloid leukemia (AML) blast cells over the course of 
induction therapy in multiple AML patients. Dr. Ferrell aimed to determine whether changes in phenotypic 
heterogeneity correlated with patient therapy response, and I chose to collaborate with him on this project 
because it provided an ideal use case for the development and application of a single-cell level metric of sample 
heterogeneity. Together, we developed the conceptual framework for quantifying cellular heterogeneity based 
on distances between cell populations in reduced-dimensional phenotypic space. I developed a workflow for this 
analysis using viSNE in Cytobank (www.cytobank.org) as the first step and, for the second step, an R script that 
calculated the Euclidean distances between pre-defined population centers on viSNE maps. Dr. Ferrell and I 
applied this workflow and R script to the data presented here, and we ultimately found that an increased 
phenotypic distance between blast cells and normal hematopoietic stem cells correlated with poor patient 
outcome.  
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Abstract  
The plasticity of AML drives poor clinical outcomes and confounds its longitudinal detection.  However, the 
immediate impact of treatment on the leukemic and non-leukemic cells of the bone marrow and blood remains 
relatively understudied.  Here, we conducted a pilot study of high dimensional longitudinal monitoring of 
immunophenotype in AML.  To characterize changes in cell phenotype before, during, and immediately after 
induction treatment, we developed a 27-antibody panel for mass cytometry focused on surface diagnostic 
markers and applied it to 46 samples of blood or bone marrow tissue collected over time from 5 AML 
patients.  Central goals were to determine whether changes in AML phenotype would be captured effectively by 
cytomic tools and to implement methods for describing the evolving phenotypes of AML cell subsets.  Mass 
cytometry data were analyzed using established computational techniques. Within this pilot study, longitudinal 
immune monitoring with mass cytometry revealed fundamental changes in leukemia phenotypes that occurred 
over time during and after induction in the refractory disease setting.  Persisting AML blasts became more 
phenotypically distinct from stem and progenitor cells due to expression of novel marker patterns that differed 
from pre-treatment AML cells and from all cell types observed in healthy bone marrow.  This pilot study of single 
cell immune monitoring in AML represents a powerful tool for precision characterization and targeting of resistant 
disease. 
Introduction 
Acute myeloid leukemia is one of the deadliest adult cancers. The five-year overall survival is 21.3% for all ages 
and 4.6% for individuals 65 and older (2013).  Current standard of care therapy has remained relatively 
unchanged over the last 30 years despite efforts to improve these poor outcomes (Stein and Tallman 2012).  
AML genetic heterogeneity has been well characterized as contributing to poor outcomes (Valk, Verhaak et al. 
2004, Patel, Gönen et al. 2012, Walter, Shen et al. 2012), and longitudinal genetic analyses have suggested 
multiple models of clonal evolution to explain disease aggressiveness (Ding, Ley et al. 2012, Klco, Spencer et al. 
2014).  While it is clear that cell subsets within a pretreatment leukemia cell population have differential responses 
to therapy, it is not known to what extent genetic and non-genetic cellular features confer these differential 
responses.  A single-cell understanding of AML therapy response over time during early treatment will 
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characterize how different treatments reprogram AML cell phenotypes and impact clonal dynamics.  Immediate 
post-treatment changes may have lasting impacts on long term outcomes, and a better understanding of how 
AML cells change following treatment may highlight key targets of opportunity for new treatments.  Mass 
cytometry and unsupervised tools from machine learning provide a new opportunity to comprehensively characterize 
cellular heterogeneity and improve our understanding of how different treatments impact AML cell biology.  In 
particular, it would be useful to characterize AML cells that remain immediately following treatment and determine 
whether they are distinct in a way that might be therapeutically targeted. 
Immunophenotype characterization by flow cytometry has become part of standard of care in AML for diagnosis 
and disease monitoring, and standard antibody panels have been published for traditional fluorescence flow 
cytometry used in clinical pathology (Stetler-Stevenson, Davis et al. 2007, van Dongen, Lhermitte et al. 2012).  
A key strength of flow cytometry is the ability to measure several independent properties on each cell and to use 
complex combinations of these quantitative measurements to classify or isolate cells of interest (Krutzik, Irish et 
al. 2004, Irish, Kotecha et al. 2006).  Surface antigens, such as CD34 and CD123, have been extensively studied 
individually or in small combinations, but reported associations with clinical outcome are numerous and often 
conflicting (Mason, Juneja et al. 2006).  Additionally, leukemia stem cells (LSCs) and stem-ness properties likely 
play a significant role in therapy resistance and leukemia persistence in AML (Eppert, Takenaka et al. 2011). 
Furthermore, the markers that characterize an AML at diagnosis may shift during treatment and be changed 
dramatically in the case of minimal residual disease (MRD) or relapse (Baer, Stewart et al. 2001). Small antibody 
panels focused on positive identification of AML cells are susceptible to overlooking AML clones that undergo 
antigenic changes.   
In contrast, measurement of 30 or more features by mass cytometry (Bendall, Simonds et al. 2011) can 
comprehensively characterize normal myeloid cell populations and, in combination with unsupervised machine 
learning tools, robustly characterizes all non-AML cells and distinguishes them from AML blasts (Becher, 
Schlitzer et al. 2014).  Mass cytometry thus gives the potential for improved ability to define subsets throughout 
therapy.  Because high-dimensional mass cytometry generates significantly more data than a traditional flow 
cytometry experiment, it therefore creates the need for new data processing and visualization tools. Computational 
tools, especially unsupervised algorithms, organize and display high dimensional data in a way not possible with 
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traditional, supervised gating techniques (Qiu, Simonds et al. 2011, Amir el, Davis et al. 2013, Bruggner, Bodenmiller 
et al. 2014, Shekhar, Brodin et al. 2014). One such algorithm, viSNE, has been shown to be robust in its ability to 
distinguish both healthy and leukemia subsets, showing great promise for research and clinical analysis and 
visualization of cytometry data (Amir el, Davis et al. 2013, McCarthy 2013).  viSNE creates a phenotypic map of 
cells from an individual sample, or collection of samples, enabling visualization of phenotypic relationship between 
individual cells (Amir el, Davis et al. 2013). Furthermore, we have validated and published methods to use this tool 
to analyze both healthy and leukemia samples (Diggins, Ferrell et al. 2015).  Given viSNE’s particular strength in 
visualization of high dimensional single cell data, it is well-suited to identify subtle or large changes in marker 
expression across several samples. Additionally, cells with unexpected phenotypes are routinely overlooked in 
manual analysis and viSNE captures many of these overlooked cells (Amir el, Davis et al. 2013, Irish 2014).   
We present a comprehensive single cell view of AML that tracks changes in the bone marrow and blood over 
time before, during, and after treatment and relates differences in cellular phenotype between patients over time 
and between cells from AML patients and healthy donors. From each patient, up to 12 samples of blood and 
marrow were obtained before, during, and after induction chemotherapy (n = 46 total samples; 14 marrow and 
32 blood from 5 individual patients).  This analysis represents a pilot of in-depth longitudinal monitoring of AML 
during induction therapy with mass cytometry. Additionally, machine learning analysis tools and mass cytometry 
were used to create a phenotypic stem-ness index for AML and applied to evaluate longitudinally collected 
patient samples.    
Materials & Methods 
Patients and Consent 
Patients with suspected AML were consented for protocol sample collection.  Healthy bone marrow was obtained 
from leftover sample from diagnostic analysis of non-cancerous tissue in the Vanderbilt Immunopathology core.  
All specimens were obtained in accordance with the Declaration of Helsinki following protocols approved by 
Vanderbilt University Medical Center (VUMC) Institutional Review Board (IRB).  For each patient participating in 
the collection protocol, signed, written consent was obtained via a written consent form that was also approved 
by the VUMC IRB. Eligibility criteria included >=18 years of age with suspected acute myeloid leukemia 
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undergoing clinical evaluation at VUMC. Patients diagnosed with AML, excluding acute promyelocytic leukemia, 
who were treated with intensive induction chemotherapy, were eligible for complete collection protocol, 
regardless of induction regimen (individual regimens noted in Table 3-1).  Basic clinical characteristics for each 
patient are listed in Table 3-1. One normal bone marrow was obtained from Vanderbilt Hematopathology Lab.  
Table 3-1 – Patient characteristics and clinical outcomes 
ID Age Sex Alive§ 
Survival 
(months) 
BM 
Blast 
WBC 
PB 
Blast 
Cytogenetics FLT3 NPM1 Induction 1 Induction 2 Relapse 
F00
1 
23 F + 14.5 97.5 
432
* 
95 
46,XX,t(9;11)(p22;q23
)[20] 
Neg Neg CR N/A N/A 
F00
2 
77 M  9 26 3.2 23 
42~47,X,-
Y,add(2)(p11.2), 
-
5,add(6)(p12),add(7)(
q22), 
add(12)(p13),del(12)(p
12), 
-15,-18,-19,-
20,+1~5mar 
Neg Neg CR N/A 3 
F00
3 
61 M  4.5 88.5 15.7 94 
46,XY,del(11)(q21q23
)[2]/46,XY[20] 
Neg Neg 
Residual 
Leukemia 
Residual 
Leukemia 
N/A 
F00
4 
49 F + 15 45 5.7 28 46, XX[20] Neg Neg 
Residual 
Leukemia 
CR N/A 
F00
7 
59 F + 14 52 1.8 0 
47,XX,+22[3]/46,XX[1
7] 
Neg Neg CR N/A N/A 
§ ‘+’ indicates patient was alive at time of last follow-up. 
* Patient F001 underwent leukapheresis prior to treatment and sample collection. 
 
 
After patients were consented, bone marrow and peripheral blood samples were obtained per protocol. 
Peripheral blood samples were collected at time of diagnosis or initial evaluation, every 2-3 days during the first 
two weeks of induction, day 14 (mid-induction) and at time of hematologic recovery, if applicable (Figure 3-1A). 
Bone marrow (BM) was collected at all clinically indicated time points, including diagnosis, mid-induction (day 
14), and hematologic recovery, if applicable.  
Sample Processing and Preservation  
Once obtained, samples underwent immediate density gradient separation of mononuclear cells using BD 
Vacutainer® CPT™ Cell Preparation Tube with Sodium Heparin (BD Biosciences, Franklin Lakes, NJ). The 
separated mononuclear cells were then pelleted with low speed centrifugation (200 x g) and aliquoted into 
41 
 
multiple cryotubes in an 88% fetal bovine serum (FBS) + 12% DMSO solution. Samples were stored at -80 C for 
24-72 hours prior to long-term storage in liquid nitrogen.  
Mass Cytometry 
Aliquots of cryopreserved samples were thawed into 10ml of warm media (90% RPMI 1640 (Mediatech, Inc., 
Manassas, VA) + 10% fetal bovine serum (Gibco® standard FBS, life technologies, Grand Island, NY)), pelleted 
by centrifugation at 200 x g, washed with warm media and pelleted again at 200 x g before resuspension in flow 
cytometry tubes with warm media (Falcon 2052, BD-Biosciences, San Jose, CA) and allowed to rest for 30 
minutes in a 5% CO2 incubator at 37 °C.  Each rested sample was then pelleted at 200xg, washed with phosphate 
buffered saline (HyClone®, HyClone Laboratories, Logan, UT), pelleted and resuspended in cell staining media 
(CSM=PBS + 1% bovine serum albumin (BSA)) (Fisher Scientific, Fair Lawn, NJ).  Cells were stained with a 
mass cytometry antibody panel of 27 antibodies (DVS Sciences, Sunnyvale, CA) designed based on inclusion 
of both consensus standard of care immunophenotyping panels for AML, as well as antibodies that allowed 
identification of non-AML PBMC (Table 3-2) (Stetler-Stevenson, Davis et al. 2007).  A master mix of these 
antibodies was added to each sample to give a final staining volume of 50µL and incubated at room temperature 
for 30 minutes.  Cells were then washed twice, first with CSM and then with PBS and then permeabilized in -20 
°C 100% methanol for 20 minutes.  Following permeabilization, cells were washed, stained with 250 nM Iridium 
intercalator (ORNATSKY, LOU ET AL. 2008) (Fluidigm, San Francisco, CA) for 16 hours at 4 °C, washed twice 
in PBS, and then re-suspended in 500 µL ddH2O for CyTOF analysis.  Samples were analyzed using a CyTOF 
1.0 at the Vanderbilt Flow Cytometry Shared Resource.  
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Table 3-2 –  
AML mass cytometry panel 
Target (Clone) Type Mass 
CD235a (HIR2) β 141 
CD19 (HIB19) γ 142 
CD117 (104D2) α 143 
CD11b (ICRF44) α 144 
CD4 (RPAT4) β 145 
CD64 (10.1) β 146 
CD7 (CD7-6B7) α 147 
CD34 (581) α 148 
CD61 (VI-PL2) β 150 
CD123 (6H6) γ 151 
CD13 (WM15) α 152 
CD62L (DREG-56) γ 153 
CD45 (HI30) α 154 
CD183 (G025H7) γ 156 
CD33 (WM53)  α 158 
CD11c (Bu15) γ 159 
CD14 (M5E2) α 160 
CD15 (W6D3) α 164 
CD16 (3G8) α 165 
CD24 (ML5) γ 166 
CD38 (HIT2) α 167 
CD25 (2A3) β 169 
CD3 (UCHT1) γ 170 
CD185 (51505) α 171 
HLA-DR (L243) α 174 
CD184 (12G5) γ 175 
CD56 (CMSSB) α 176 
Iridium § 191 
Marker type key: 
α – Consensus AML  
β – Secondary AML  
γ – Other  
§ - Mass cytometry  
 
Table 3-2. Table of antibodies for mass cytometry. Antibodies used for mass cytometry staining are listed in this table. 
Clone of the antibody along with designation of type and mass number are listed for each antibody. Antibody “type” in this 
table is based on markers recommendations for AML phenotyping by the Bethesda International Consensus Conference 
(Wood, Arroz et al. 2007). 
Data Analysis  
Mass cytometry data (.fcs) files were evaluated using R (version 2.5.2, The R Foundation for Statistical 
Computing), viSNE in MATLAB (version R2013b, The Mathworks, Inc.), and Cytobank software (Cytobank Inc.) 
(KOTECHA, KRUTZIK ET AL. 2010, AMIR EL, DAVIS ET AL. 2013). Files from each patient were mapped using 
the viSNE MATLAB graphical user interface, cyt, available at 
http://www.c2b2.columbia.edu/danapeerlab/html/cyt.html. Files used for viSNE co-analysis had the same 
number of cells randomly sampled from each file, unless very few cells were collected for a particular time point, 
in which case all cells were used in viSNE analysis.  
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Measuring Hematopoietic Stem Cell Distance within viSNE 
Within a given viSNE map, the hematopoietic stem cell distance (HSCD) for a given cell was calculated as the 
standard Euclidean distance formula (√(𝑥2 − 𝑥1)2 + (𝑦2 − 𝑦1)2) where 𝑥1, 𝑦1 was the coordinate location of a 
cell on the viSNE map’s t-SNE axes and 𝑥2, 𝑦2 was the center of the healthy HSC population on the same viSNE 
map. In particular, CD34+ CD38lo/- hematopoietic stem cells were used as a common reference point for 
comparing non-leukemia subsets and phenotypically diverse AML samples. The center of the healthy HSC 
population was determined by averaging the x and y coordinates of the HSCs in the viSNE map.  A population’s 
HSC distance was calculated as the mean HSC distance of all cells in that group.   For comparison of healthy 
and leukemia inter-sample heterogeneity, mass cytometry .fcs files of healthy PBMC (Nicholas, Greenplate et 
al. 2015) and bone marrow (Amir el, Davis et al. 2013) were used from published sources and remapped in 
separate viSNE analyses. Distances of common cell populations were measured from designated cells 
populations, HSC in the case of marrow samples and CD4+ T cells in the case of PBMC.  Distances of these 
populations found in each sample were measured from reference population as described above and median 
and interquartile range (IQR) values were calculated to give a measure of inter-sample heterogeneity within 
healthy and AML samples.  
Results  
Machine Learning and Mass Cytometry Separated AML Blast Cells from Non-Malignant Cells 
AML blast cells were identified in viSNE using a combination of marker expression and localization on the 2–
dimensional viSNE map.  In each sample, a discrete group of cells was identified in the viSNE map characterized 
by a phenotype consistent with myeloid blasts (Figure 3-1B). Measured blast percentages were consistent with 
those reported for clinical pathology evaluation (data shown for F001 and F003 in Figure 3-5). Furthermore, other 
discrete islands within the map represented known populations of non-malignant mononuclear cells if present 
(Figure 3-1B and 3-1C). These islands were high for CD45 expression. Each island was characterized by 
analysis of each marker measured in that population and was assigned a cell identity (Figure 3-1B).  
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viSNE Distance from Stem Cells Provides a Common Measure of Phenotypic Similarity to Stem Cells 
In a viSNE map, proximity corresponds to phenotypic similarity according to the 27 measured proteins selected 
when creating the viSNE axes.  To investigate the phenotypic similarity of non-leukemia mononuclear cells to 
stem cells, healthy bone marrow mononuclear cells and gated blast cells from four diagnostic AML bone marrow 
samples were mapped with viSNE (Figure 3-2A).  Populations identified within a healthy sample included 
hematopoietic stem cells (HSCs), early progenitors (EPs), dendritic cells, maturing myeloid cells, monocytes, 
natural killer (NK) cells, CD4+ and CD4- T cells and B cells. Phenotypic distance from HSCs was then used to 
characterize healthy and AML population.  Healthy NK cells and T cells were the most phenotypically distinct 
from HSC with distances of 46.6 (NK), 54.1 (CD4+ T cells), and 60.4 (CD4- T cells).  CD34+ CD38+ bone marrow 
cells comprised the majority of the EP population.  EPs occupied the largest area of phenotypic space relative 
to the number of cells in the population, indicating that EPs were the most heterogeneous cell population 
observed.  The mean distance of EPs from HSCs was 12.4, indicating that, on average, EPs were the healthy 
cell type most closely related to the HSCs, as expected. EPs were phenotypically similar to healthy stem cells 
when considering 27 protein features (Figure 3-2B).  This calculated HSC distance was used to quantify the 
phenotypic distance of each patient’s AML blasts from known cell populations within healthy marrow.   
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Figure 3-1. Overview of mass cytometry phenotyping in early AML therapy  
(A) A timeline of AML induction shows blood and bone marrow collection scheme for this study. (B) viSNE analysis of all 
live cells from the diagnosis marrow of one AML patient F004 is shown.  Cells were arranged on the viSNE map along 
unitless x and y viSNE axes according to 27-dimensional phenotype (Table 3-2) so that phenotypically similar cells were 
placed near each other.  Cellular abundance is indicated with a shaded contour plot where outliers start at 10% and each 
2% contour is shaded a lighter color from purple to yellow.  (C)  On the same viSNE axes as in (B), diagnostic bone 
marrow cells from patient F004 were graphed and shaded according to identity determined by immunophenotype.  AML 
blast cells were shaded red and non-blast cells were shaded grey.  (D) On the same viSNE axes as in (B), diagnostic 
bone marrow cells from patient F004 were graphed and shaded according to expression of CD45 on a rainbow heatmap 
(log-like arcsinh15 scale). 
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Figure 3-2. Phenotypic distance from hematopoietic stem cells distinguishes healthy cell populations and AML 
blasts from different individuals.  (A) A 27-dimensional viSNE analysis compares an equivalent number of live cells 
from normal bone marrow and from each of four AML patient bone marrow samples obtained at diagnosis prior to 
treatment. (B) 27-dimensional phenotypic distance of normal bone marrow mononuclear populations from healthy 
hematopoietic stem cells (HSCs) was measured in the viSNE analysis from (A) and is shown in blue.  (C) As in (B), the 
HSC distance for the blast populations from four AML patients was measured and is shown in blue.   
Diagnostic AML Blasts from Four Patients Differed in Phenotypic Distance from HSCs 
Within the viSNE map, HSC distance was measured for AML blasts from four patients’ diagnostic samples 
(Figure 3-2C).  AML blasts localized to one general area of the viSNE map; however, while samples from F003, 
F004, F007 were associated closely, AML blasts from patient F002 were phenotypically distinct and well 
separated from other AMLs (Figure 3-2A).  In contrast with healthy early progenitor cells, AML blasts were more 
homogeneous in phenotype, as AML blasts occupied a smaller phenotypic area of the map than EPs (Figure 3-
2A).  This was despite the fact that AML blast populations contained approximately 5.4 times as many cells as 
the EP population in this analysis.   
AML blasts from patients F003 and F004 were phenotypically similar to healthy HSCs and had very low distance 
values near 10.  This result contrasted with that from AML patients F002 and F007, whose diagnostic blasts 
were farther from healthy stem cells and had distance values near 30 (Figure 3-2), highlighting the patient-to-
patient diversity that can be detected with even a small cohort of patients.  By comparing distance to HSC and 
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other populations on the viSNE map, each patient’s AML blasts were characterized as phenotypically more 
similar to HSCs (F003, F004) or more distant from HSCs (F002 and F007) (Figure 3-2B).   
To assess donor variation for this type of comparison for other cell subsets, distances on viSNE axes were 
compared for 5 sets of test and reference populations from this manuscript and others and reported as the 
interquartile range (IQR) and median across individuals.  Little heterogeneity in viSNE distances was observed 
when comparing CD4+ T cells from healthy PBMC to B cells from healthy PBMC (IQR: 1.3, median: 38.1, N = 
7).  Similarly, relatively little heterogeneity was seen in comparisons of healthy BM B cells to healthy BM HSCs 
(IQR: 4.5, median: 10.1, N = 3), non-leukemia CD4+ T cells from AML BM to healthy BM HSCs (IQR: 2.7, median: 
9.5, N = 3), and non-leukemia CD4+ T cells from AML BM to healthy BM HSCs (IQR: 2.4, median: 7.3, N = 3).  
All of these low interquartile ranges contrasted with the significantly greater heterogeneity seen when comparing 
AML blasts compared to healthy BM HSCs here (IQR: 18.6, median: 17.7, N = 4, Figure 3-2).  Thus, the 
heterogeneity in viSNE distance was specific to the leukemic blasts and not observed in comparisons including 
non-leukemia cells from the same sample, healthy blood, or healthy bone marrow. 
 
Mapping Early Treatment Samples in viSNE Allowed Accurate Assessment of Blast Clearance  
In order to assess whether this technique properly characterized blast clearance, samples over time from 
individual patients were mapped in patient-specific viSNE analyses.  A leukemic blast area or island was 
identified in the viSNE map and treatment response was observed as the regression or persistence of cells within 
this area over time. In patients who achieved remission (based on clinical pathology assessment), >95% of cells 
in the recovery samples were outside of the leukemic blast area (Figure 3-3, Figure 3-4, Figure 3-5).   
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Figure 3-3 – Comprehensive analysis of AML therapy response kinetics.  viSNE analysis characterizes changes in 
leukemia cell phenotype over time for cells from all treatment times for three individuals. All cells from all clinical 
timepoints were analyzed using viSNE according to the 27 markers measured (Table 3-2).  An AML blast area was 
identified as in Figure 3-1.  Color indicates clinical time point and source, either bone marrow or blood.  Patients F002 and 
F007 had very low blast percentages in the peripheral blood at diagnosis.   
 
Abundance and phenotype of AML cells changed significantly in the blood during the first days of treatment, with 
significant variability among patients (Figures 3-3 & 3-4). Absolute numbers of all cell types, malignant and non-
malignant, declined predictably in the blood of all patients by Day 14.  Lymphocytes, predominantly T cells, were 
the most abundant cell population in all patients at Day 14, when leukocyte counts in marrow and blood are 
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typically at their nadir.  Leukemic blasts in the blood and marrow formed distinct islands in viSNE and these 
islands could be followed over time for each patient (“Leukemic Blast Area”, Figures 3-3 & 3-4).  Cells were 
observed largely to regress from this area in blood by day 14 in all patients (>90%).  The patient with the highest 
Day 14 blast population (F003) also had the highest percentage of blasts seen in the bone marrow (see below).  
Overall, the mass cytometry results were comparable to those obtained by clinical pathology analysis (Figure 3-
5).   
Mid-induction (Day 14) bone marrow aspirate was obtained from patients when sufficient sample was available 
(patient F002 had inaspirable marrow at day 14, though a core biopsy revealed no residual AML).  Bone marrow 
from patients F003 and F004 was significantly involved with AML post-induction, and both patients required 
reinduction.  Patient F003 never achieved remission despite two inductions and the initial Day 14 marrow was 
highly involved by AML (90% blasts by microscopy, 81% by clinical flow cytometry).  This clinical finding was 
corroborated by mass cytometry and viSNE analysis, as both patients had cells mapped within the leukemic 
blast area at Day 14 (Figures 3-3 & 3-4). For patient F004, residual cells occupied a tight area on the map and 
were phenotypically distinct from the majority of the AML cells in the diagnostic sample, both in the marrow and 
the blood (Figure 3-3).  This residual population of AML cells did not persist in the second mid-induction biopsy 
(Day 14-2) or at recovery biopsy (after second induction), when the (Amir el, Davis et al. 2013)(Amir el, Davis et 
al. 2013)(Amir el, Davis et al. 2013)(Amir el, Davis et al. 2013)(Amir el, Davis et al. 2013)(Amir el, Davis et al. 
2013)(Amir el, Davis et al. 2013)(Amir el, Davis et al. 2013)patient was found to be in remission.  Thus, a 
population of leukemia cells from F003 and F004 persisted after the initial treatment and a change in overall 
AML cell phenotype was observed in this persistent population in both cases.  
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Figure 3-4. Computational analysis of samples throughout induction allows visualization of both remission and 
persistent AML.  27-dimensional viSNE analysis of all live cells from all sample collection time points for two AML 
patients is shown (left).  Clinical response is indicated for each patient on the left. Leukemic blast areas were determined 
by location of cells at diagnosis and analysis of marker expression, as in Figure 3-1. At right, cells taken from the time 
point shown (red) were compared to all cells (grey). Differences in the location of cells within the viSNE map resulted from 
changes in protein expression.  
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Figure 3-5. Analysis of immunophenotypic change throughout induction - F001 and F003.  At top, mass cytometry 
quantification of blast percentage for each sample from two patients is shown. Below, clinical cytometry and microscopy 
data of each blood (clinical samples collected at different time on same day) and bone marrow (clinical and research 
samples collected at same time) sample throughout induction is shown. The patient whose samples are displayed on the 
left (F001) achieved remission (defined as <5% marrow blasts at recovery). On the right, a refractory patient’s samples 
are shown, in whom a very high blast percent were seen at day 14.  
 
 
Mass Cytometry Identified Phenotypically Distinct Persisting AML Blasts That Were Rare Pre-
Treatment 
In post-treatment bone marrow from patient F003, discrete populations of persisting cells made up the majority 
of the sample (80%). In order to perform a more direct comparison of pre- and post-treatment AML blasts, these 
blast populations were gated from Day 0 and Day 14 bone marrow and remapped in viSNE. They were then 
visualized in order to demonstrate subpopulations based on cellular abundance (Figure 3-6A).  Thirteen AML 
cell populations were identified based on phenotype and abundance in pre-treatment and post-treatment 
samples.  Of these AML cell populations from patient F003, 6 populations were abundant pre-treatment and 7 
totally distinct populations were abundant post-treatment (Figure 3-6A).  
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Figure 3-6. Rare subsets at diagnosis become prominent after treatment in a patient with refractory AML.  (A) 
Blasts from Day 0 and Day 14 were gated out from prior viSNE maps for patient F003 (shown in Figure 3-4) and 
remapped in viSNE together.  Gates were drawn around subpopulations and based on relative cell abundance, as in 
Figure 3-1B. (B) Percent of total blasts for each gate at both time points.  (C) A heat map of median marker expression for 
each gate at both time points is shown.  
 
Overall, the AML phenotype shifted markedly post-treatment.  Over 85% of cells post-treatment were groups into 
7 phenotypic regions as mentioned above. By contrast, fewer than 10% of the cells fell into these regions pre-
treatment (Figure 3-6B).  The subpopulations observed post-treatment ranged in abundance from 2.3% to 20% 
of the AML cells.  At diagnosis, in the pre-treatment sample, these populations constituted as little as 0.6% to 
1.8% of total blasts (Figure 3-6B).   
Increased Expression of CD34, CD38 and CD184 Characterized Post-Treatment Persistent AML 
While Subpopulations Displayed Significant Heterogeneity  
Individual marker changes contributing to overall shift were then characterized. Several markers of leukemia 
stem cells were identified as contributing to the overall shift in phenotype in samples from patient F003 (Figure 
3-6C and Figure 3-9).  Median marker expression within the 13 identified subsets was calculated and visualized 
as a heat map (Figure 3-6C).  Prominent changes seen in the pre- to post-treatment samples include both overall 
increases and decreases in specific markers.  Among these markers were CD34, CD38, and CXCR4/CD184, 
which respectively increased by 0.7, 0.9, and 0.6 fold on the log-like asinh15 scale.  Expression of CD117 and 
CD123, markers associated with LSC ability, decreased in the post-treatment sample. In non-leukemic cells, 
53 
 
expression of CD34, CD38, and major cell type identity markers (e.g. HLA-DR, CD4, CD19) did not significantly 
change over time on non-AML cells (all <0.2 fold, Figures 3-7 and 3-8).   
 
Figure 3-7 - Changes in individual markers over time during treatment on AML blasts from patient F003.  Biaxial 
plots summarize six clinical timepoints (rows) for 24 markers (sets) for the AML blast cells from patient F003, gated as 
shown in Figure 3-4.  The indicated marker is plotted on the x-axis using the same arcsinh15 scale as in other figures (e.g. 
Figure 3-1B).  Plot labels are omitted to save space.  The y-axis is mass cytometry event length, which is used here to 
spread the events out in the y-axis to create a compressed band plot view that allows rare subsets to be observed (see 
e.g. CD235a) that would be obscured in a traditional 1D histogram view. 
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Figure 3-9 - Changes in individual markers over time during treatment on non-leukemia cells from patient F003.  
As in Figure S2, biaxial plots summarize six clinical timepoints (rows) for 24 markers (sets) for the non-leukemia cells from 
patient F003, gated as everything not in the leukemia blast gate shown in Figure 3-4.  The indicated marker is plotted on 
the x-axis using the same arcsinh15 scale as in other figures (e.g. Figure 3-1B).  Plot labels are omitted to save space.  
The y-axis is mass cytometry event length, which is used here to spread the events out in the y-axis to create a 
compressed band plot view that allows rare subsets to be observed (see e.g. CD16) that would be obscured in a 
traditional 1D histogram view. 
 
Analyses limited to overall changes in the entire population of persistent cells belie the underlying heterogeneity 
seen in individual subpopulations of cells, where changes are quite diverse. Though CD117/c-kit expression 
showed a large decrease from initial sample to post-induction sample, the heat map and biaxial plots 
demonstrate that expression of this marker is heterogeneous and remains high in one subpopulation (population 
7 in Figure 3-6C and Figure 3-9).  Subpopulation 7 is also notable for increased expression of CD33 and 
CD184/CXCR4, which are both quite low in all of the prominent pre-treatment populations (Figure 3-9). Based 
on this, it is apparent that a heterogeneous group of subpopulations constitute AML before and after treatment.  
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Thus, the overall shift in AML phenotype was driven by the differential abundance of phenotypically distinct 
subpopulations that were rare pre-treatment (Figure 3-6A-C). 
 
 
Figure 3-9. Single cell analysis of immunophenotype in AML subpopulations before and after therapy response.  
Biaxial density plots show the markers with the highest standard deviation across subsets compared with CD34 on individual 
cells in live bone marrow AML blasts from patient F003.  Columns show AML blast populations identified (Figure 3-6) from 
Day 0 or Day 14, whichever was more abundant.  Red boxes highlight key changes in protein expression discussed in the 
text.  Standard deviation (SD) of each row’s marker across all populations is indicated to the right of the plots.  Stem index 
(Figure 3-2) of each population is indicated above each column.  CD34 and the top 11 most variable markers were graphed.  
CD4 was included as an example of a low expression marker that did not change.   
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Marker Expression Varied Among Subpopulations 
To quantify variability within subpopulations, we calculated the standard deviation of each marker among all 13 
subpopulations identified in pre- and post-treatment samples. The most variable markers among the 
subpopulations are shown in Figure 3-9, with the exception of CD4, which was a negative, non-variable marker 
on these leukemia subpopulations. HLA-DR displayed the most variability (SD=1.0), followed closely by CD61 
(SD=0.91) and CD62L (SD=0.86). Expression of these markers ranged from high expression to little or no 
expression across the 13 populations, with variability seen in both pretreatment and post-treatment samples. 
Interestingly, population 8 was identified as having little or no expression of most markers that identified leukemic 
blasts, though this population was seen in both pre-and post-treatment samples and its constituent cells were 
identified in the initial gating schemes (Ir+, single cells).  
Persisting AML Cells Become Less Phenotypically Stem-Like 
In order to understand how individual marker changes affected overall phenotypic diversity and identity with 
respect to known, healthy populations, pretreatment (Day 0) and post-treatment populations (Day 14) blast cells 
were mapped in viSNE with the normal healthy marrow population. Based upon the resultant viSNE map, 
phenotypic shifts were quantified and AML blasts were shown to be less phenotypically similar to healthy HSCs 
following treatment (Figure 3-10B).  For this analysis, predominant bone marrow blast populations at diagnosis 
(AML subsets 1 - 6) were mapped with normal marrow and major persisting populations from day 14 (subsets 7 
- 13) (Figure 3-10A&B).  Post-treatment, the mean change in HSC distance was +10.0, indicating a phenotypic 
shift away from HSCs (Figure 3-10B). Taken together, these data indicate that the overall trend is for AML blasts 
to gain a novel phenotype that is distinct from those of healthy stem and progenitor cells in the bone marrow.   
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Figure 3-10. Blast populations become increasingly phenotypically different from both differentiated cells and non-
malignant hematopoietic stem cells. 27-dimensional viSNE analysis compared normal bone marrow cells, AML blasts 
from Day 0 from patient F003 (subpopulations 1-6 only), and AML blasts from Day 14 from patient F003 (subpopulation 7-
13 only). (A) Normal bone marrow mononuclear cells are shown (left). A cartoon outline of the major healthy subpopulations 
was identified and HSC distance measured (right).  (B) Pre-treatment (day 0) and post-treatment (day 14) samples are 
compared same map as in (A) and HSC distance of each subpopulation is shown. 
 
Discussion 
This work characterizes changes in AML blasts and healthy cells over time following induction chemotherapy 
according to 27 protein features, including the vast majority of diagnostic markers for this disease.  A key benefit 
of this approach is that it reveals whether AML cells are cleared, phenotypically altered, or left unchanged after 
treatment.  This approach directly measures the impact of treatment on the cellular milieu of the patient’s marrow 
and blood.  By identifying persistent AML cells post therapy, mass cytometry and computational analysis 
provided a clear picture of AML subpopulation dynamics in the early therapy response and revealed the 
unexpected finding that AML “persister” cells can become significantly less phenotypically stem-like immediately 
following treatment. These results provide a foundational reference for understanding the reservoir of AML cells 
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that evade treatment and provide a proof of concept for high dimensional single cell characterization of clinically 
relevant cell-surface molecules in AML.   
While this study assessed samples from 5 patients, there are 46 samples in total that have been analyzed.  
Regardless, this pilot study assessed the feasibility of greatly expanded longitudinal monitoring of AML to capture 
differentiation and cell subset dynamics. AML displays significant phenotypic plasticity in the clinical setting 
(Baer, Stewart et al. 2001). However, this phenotypic heterogeneity is not well represented in focused fluorescent 
cytometry panels measuring between six and eight features.  Here we do not intend to duplicate work done by 
large clinical flow consortia, such as EuroFlow, rather we intend to demonstrate the utility and feasibility of this 
approach (van Dongen, Lhermitte et al. 2012, van Dongen, Orfao et al. 2012). Larger studies of high-dimensional 
immune cell monitoring in AML are now needed to further validate this approach and to begin to understand 
treatment specific changes. This study demonstrates potential drawbacks of small fluorescence cytometry 
panels used to distinguish the leukemia blasts at during therapy – namely that changes in certain markers may 
be missed by small panels.  The results of this study also indicate that immunophenotype in AML is highly plastic 
and can fundamentally shift in a matter of days in response to treatment to adopt a pattern that is both abnormal 
and not HSC-like.  Furthermore, while this study was not designed to determine whether or not chemotherapy is 
altering cell phenotypic expression or selecting for persistent cells, the kinetics of early marker change in the 
peripheral blood indicate that phenotypic plasticity is possible.   
This focused pilot study indicates that mass cytometry is feasible for clinical immune monitoring of treatment 
impact in blood cancers, such as AML.  Furthermore, these findings are immediately translatable to longitudinal 
studies of other hematologic malignancies, chronic viral infections, and autoimmune disorders.  Early phenotypic 
changes may also be evaluated in the peripheral blood blasts, when present, and could give key insight to early 
treatment success. It has been shown that early blasts decline in peripheral blood can predict complete remission 
rates in AML (Gianfaldoni, Mannelli et al. 2006, Elliott, Litzow et al. 2007, Arellano, Pakkala et al. 2012). With 
added information of high-dimensional directionality and phenotypic distance changes, peripheral blood changes 
can be better characterized early and could become even more informative.  However, because peripheral blasts 
can have a slightly different immunophenotype than bone marrow blasts (as in F001), changes in blasts post-
therapy are likely best evaluated within the same compartment.  Visualization of high-dimensional relationships 
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within viSNE allow for assessment of changes over time as well as noting any differences between different 
compartments (e.g., marrow vs. blood).  The approach presented here also provides a new clinical tool for 
tracking and dissecting cellular identities and functional responses in clinical studies and translational research.  
For example, the markers identified here can now be used to sort persister-like cells from pre-treatment AML 
and determine whether these cells are genetically related to the persister cells.  Recently published data reveals 
the decoupling of immunophenotype and signaling in AML samples at diagnosis and shows that the presence of 
“primitive” signaling profiles found in healthy HSCs likely more prognostic than phenotype (Levine, Simonds et 
al. 2015).  Applying this finding to our data, we would predict that refractory AML adopts a more “primitive” 
signaling pattern post-treatment, regardless of phenotypic changes. In this way, application of signaling 
measurements to longitudinal monitoring in AML has great potential to reveal signaling and phenotypic markers 
of resistance that could improve disease targeting.   
This study describes a novel phenotypic stem-ness index based on the high dimensional immunophenotype of 
normal and leukemia samples.  It is possible that the majority of post-treatment cells are leukemia stem cells 
and their phenotypic changes reveal a level of plasticity in stem cell phenotype that cannot to be assessed 
outside of real world treatment situations.  Importantly, some of this plasticity has been seen in vitro as well 
(Eppert, Takenaka et al. 2011, Sarry, Murphy et al. 2011).  It is possible that regardless of their “stem-ness”, as 
defined either by phenotype or function, these therapy resistant cells are the cells that warrant further 
investigation and therapeutic focus in the context of AML, as it is their persistence post-treatment that results in 
the ultimate death of patients.  We have shown that subsets present in a refractory AML display increased 
expression of CD34, CD38, and CD184 while viSNE analysis shows that these cells “move away” from healthy 
stem cells and the bulk of the original disease. These cells went in a new direction immunophenotypically, 
maintaining many AML cell characteristics while also adopting new features. Furthermore, this could indicate 
some subtle maturation, however abnormal, within the blast population induced by the treatment.  It would not 
be completely unexpected for LSCs to switch immunophenotype, as though LSCs were first described as Lin- 
CD34+ CD38lo/, it is well-established that cells with leukemia initiating ability and stem-ness properties exist 
outside of this original definition (Taussig, Miraki-Moud et al. 2008, Taussig, Vargaftig et al. 2010, Goardon, 
Marchi et al. 2011, Sarry, Murphy et al. 2011).  This may be especially true in cases of refractory AML. 
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Additionally, the expression of CD184 has been linked to worse outcomes in AML and therapeutic targeting of 
this molecule has been reported (Spoo, Lubbert et al. 2007, Nervi, Ramirez et al. 2009). 
This refractory AML presented here demonstrated a large burden of persistent leukemia cells after therapy. 
These persister cells are common in AML, as evidence by MRD in patients who achieve a remission or as overt 
refractory disease.  At no point did we see AML “collapse” into a phenotypically more similar (less 
heterogeneous) population or adopt a uniform stem or progenitor cell phenotype that could imply a bottleneck 
selection event.  The response to treatment was typically an increase in diversity of phenotypes and movement 
away from traditional stem cell phenotypes.  It may be that there is an inducible mechanism of phenotypic shift 
in AML cells caused by chemotherapy.  This mechanism could depend on non-cell autonomous changes and 
inter-clonal interaction, as has recently been described in cancer cells (Marusyk, Tabassum et al. 2014). This 
would contrast with the classic “selecting for a subclone” model and aligns with some recent observations based 
on gene sequencing, which highlight genetic and functional heterogeneity within AML at diagnosis and relapse 
(Ding, Ley et al. 2012, Klco, Spencer et al. 2014). Further clarification of the functional differences in 
immunophenotypically distinct subsets of AML, particularly of intracellular signaling networks, is needed to 
identify novel therapeutic targets in this disease.  
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Preface 
Methods such as those introduced in Chapter 1 and Chapter 2 are useful for discovering phenotypically 
distinct cell subpopulations in high-dimensional, single-cell data. However, I found the characterization of 
computationally discovered subsets to be largely qualitative and subjective. There was no automated method 
for quantitatively comparing the populations that had been discovered using biaxial gating or different 
computational tools. To address this need, I developed an equation that combines magnitude and variance 
information to determine context-specific feature enrichment on a cell subset compared to a reference cell 
subset. This equation is the core of the method termed Marker Enrichment Modeling (MEM) that takes previously 
identified cell population data as input and reports a label for each subset relative to a specified reference cell 
population. Using multiple flow cytometry datasets from the analysis of human and murine tissues, I illustrated 
the ability of MEM to quantify proteins on cell subsets discovered across analysis methods, platforms, and 
tissues. The MEM equation and concept is a key component to the long-term goal of developing fully automated 
analysis workflows that can identify populations of cells from high dimensional data and subsequently 
characterize and label those cells without the need for expert interpretation. 
Abstract 
 While advances in single cell biology have enabled measurement of 35 or more features on millions of 
single cells, learning cell identity still relies on human experts.  Marker Enrichment Modeling (MEM) addresses 
the need to objectively describe cell subsets by quantifying feature enrichment and reporting a text label that can 
be used by machines and humans to learn cell type (cytotype). In datasets including healthy human blood, bone 
marrow, and tonsil, murine tissues, and human tumors, MEM identified key proteins used by experts to 
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distinguish rare and novel cell subsets.  MEM-generated labels accurately characterized phospho-protein 
signaling responses in subgroups of leukemia patients.  Algorithmic comparison of MEM label correctly identified 
80 cell populations from 7 studies of 3 human tissues measured using different instrumentation and distinguished 
tumor-infiltrating immune cell subsets and malignant cell populations in human glioma.  MEM labels thus provide 
a quantitative language to objectively communicate characteristics of new and established cell types observed 
in complex tissue microenvironments. 
Introduction 
 Quantitative cytometry workflows have developed diverse approaches to grouping cells into 
populations(Lo K 2009, Qiu, Simonds et al. 2011, Shekhar, Brodin et al. 2013, Bruggner, Bodenmiller et al. 2014, 
Mosmann, Naim et al. 2014) and visualizing results in graphs that arrange populations based on phenotype(Irish, 
Hovland et al. 2004, Bendall, Simonds et al. 2011, Bendall, Davis et al. 2014, Levine, Simonds et al. 2015, 
Spitzer, Gherardini et al. 2015). Significant features of populations are typically assumed to be those which were 
expressed at the highest median level on each population. These strategies work well when feature variability is 
low and cells match established types, but computational analysis of single cell data is now routinely revealing 
novel cells with non-canonical phenotypes(Becher, Schlitzer et al. 2014, Irish 2014, Patel, Tirosh et al. 2014, 
Greenplate, Johnson et al. 2016).  This is especially the case for diseases where abnormal expression profiles 
and signaling responses distinguish clinically significant cell subsets(Irish, Hovland et al. 2004, Irish, Myklebust 
et al. 2010, Levine, Simonds et al. 2015, Ferrell, Diggins et al. 2016, Greenplate, Johnson et al. 2016).  Existing 
statistical approaches, such as a z-score, can be used to characterize a population’s deviation from a mean, but 
may be limited to a normal distribution or may not account for both intra- and inter-population variability in a 
single metric.  
 We have developed Marker Enrichment Modeling (MEM) to quantify context-specific marker enrichment 
on populations. MEM was developed to address the idea that the most experimentally and biologically relevant 
cellular features are those that are more homogenously expressed on the majority of cells in a given population 
than on other cells in the sample or experimental framework. Additionally, features that are specifically lacking 
on a population (i.e. negatively enriched) are as important to that population’s identity as are those specifically 
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expressed at high levels (i.e. positively enriched). Given these considerations, the MEM equation was derived 
to produce a signed value for each population feature that quantifies positive and negative, population-specific, 
contextual feature enrichment. For a given subset of cells within a sample, MEM compares both feature 
magnitude and feature variability for the subset with those of a reference cell population, such as stem cells or 
other cells in the samples.  MEM quantifies the extent to which proteins or other measured features are enriched 
on a chosen cell subset compared to a selected reference population.  For each measured feature, a MEM score 
is calculated (Eq. 1). 
MEM score = ,    (MAGPOP-MAGREF) <0  MEM = -MEM        (Eq. 1)    
 In Eq. 1, POP denotes the population of interest, REF denotes the reference population to which POP 
will be compared, MAG is the magnitude of a feature (here, median protein expression detected by mass or 
fluorescence flow cytometry), and IQR indicates the interquartile range.  The ratio in IQR values is used to 
capture how homogeneously the chosen cells in POP expressed a given protein relative to REF. The reference 
population REF is chosen based on the biological comparison of interest (Figure 4-1).  Examples of REF include 
all other cells from a sample not in POP Figure 4-2, and Figure 4-13), previously-defined populations, such as 
other cells from the sample (Figure 4-6 and Figure 4-9), comparisons to cells from other individuals (Figure 4-
15), and “gold standard” populations like stem cells (Figure 4-13, Figure 4-14).  Unsupervised reference selection 
(i.e. using all non-population cells from the same sample or set of samples as POP) is advantageous when 
labeling and characterizing cell systems or microenvironments in the original biological context. Comparison to 
a common reference facilitates comparing changes in phenotype or sample quality over time, quantifying 
differences between individuals, and matching a label from a new population of cells to established reference 
populations of diseased or healthy cells.   
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Figure 4-1. Examples of MEM reference population selection to capture different contexts. Alternative reference 
populations (REF) can be used to capture how features of the test population (POP) are enriched in different contexts. 
Reference comparisons include a) all non-population cells in the sample or experiment (default), b) a population from 
another sample in the same study, c) a population from the same sample, d) multiple subsets of non-population cells from 
the same sample, e) a standard control population, and f) pairwise comparison between all populations in a sample. 
 
MEM arranges the scores calculated for each protein into a quantitative label for each POP.  For example, 
the MEM label for CD4+ T cells from healthy human tonsils identified by expert gating of mass cytometry 
data(Polikowsky, Wogsland et al. 2015) and compared to all other immune cells in the sample as REF was 
▲CD4+10 CD3+9 CD5+5 CD27+5 ▼MHCII-10 CD19-9 CD20-7 CD40-7 CD22-7 Igκ-5 Igλ-4 IgD-2 SHP1-2 CD16-2 CD33-
2 IgM-2 (Table 4-1).  In this MEM label, the exponent quantifies protein enrichment in tonsillar CD4+ T cells relative 
to the other the tonsillar leukocytes, primarily B cells.  This MEM label indicates that tonsillar CD4+ T cells are 
distinguished both by expression of canonical T cell proteins (CD3+9 CD5+5) and by a lack of expression (negative 
enrichment) of antigen presenting cell (APC) and B cell proteins (MHCII-10 CD19-9 CD20-7).  MEM scores are 
robust across tissue types and experiments; CD4+ T cells were consistent in MEM labels for the same tissue 
across healthy donors and correctly captured differences in phenotype between tissues (Table 4-1).  For 
example, tonsillar CD4+ T cells displayed significantly greater CD27 enrichment than blood CD4+ T cells (p<0.02; 
tonsillar CD4+ T cells: CD27▲5.3 ± 0.58, N=3; blood CD4+ T cells: CD27▲3.4 ± 0.98, N=7; see Table 4-1).  
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Highly enriched proteins were more important to accurate population identification than proteins with high median 
expression (Figure 4-2c; Figure 4-4; Figure 4-5).   
MEM label reporting provides a new way to objectively and quantitatively communicate cell type 
in studies of complex, dynamic tissue microenvironments, such as stem cell niches, immune 
responses, and human tumors. 
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Table 4-1 – Healthy human CD4+ T cells from various mass cytometry studies were labeled consistently by 
MEM  
Tissue Study Panel focus # MEM label for CD4+ T cells vs. other live cells 
Bone 
marrow 
Bendall  
et 
al.(Bendall, 
Simonds et 
al. 2011) 
Hematopoiesis 4 
▲CD4+10 CD3+6 
▼MHCII-3 CD8-2 CD45RA-2 CD11b-2 
Amir  
et al.(Amir 
el, Davis et 
al. 2013) 
Canonical 
immune 
5 
▲CD4+10 CD3+4 
▼CD45RA-2 
Ferrell  
et al. 
(Ferrell, 
Diggins et 
al. 2016) 
AML &  
myeloid cells 
2 
▲CD3+10 CD7+7 CD4+6 CD62L+4 
▼CD11b−6 CD11c−6 MHCII−6 CD64−5 CD61−4 CD13−3 
CD38−3 CD123−2 CD33−2 CD14−2 
Healthy 
human 
PBMCs 
Leelatian  
et 
al.(Leelatia
n, Diggins 
et al. 2015) 
Canonical 
immune 
7 
▲CD4+10 CD3+7 
▼CD8a-3 CD16-3 CD11b-2 CD69-2 MHCII-2 
Greenplate 
AR§ 
T cells 
1.3 
▲CD4+10 CD3+9 CCR7+5 CD27+5 CD28+3 CD64+2 
 
1.7 
▲CD4+10 CD3+9 CD45RO+3 CD27+3 CD64+2 CD28+2 
▼CD45RA-4 
1.1 
▲CD4+10 CD3+8 CD27+4 CCR7+3 CD64+2 
▼CD45RA-2 
1.8 
▲CD4+10 CD3+9 CD45RO+4 CD27+3 CD43+2 
▼CD45RA-5 
1.6 
▲CD4+10 CD3+7 CD27+2 
▼CD45RA-4 
1.4 
▲CD3+10 CD4+9 CD27+4 CCR7+3 CD28+2 
▼CD45RA-3 
1.2 
▲CD4+10 CD3+10 CD43+4 CD27+3 CCR7+2 CD28+2 
CD45RO+2 
▼MHCII-4 CD38-2 CD45RA-2 
Healthy 
human 
tonsil 
Polikowsky  
et 
al.(Polikow
sky, 
Wogsland 
et al. 2015) 
B cells 
3.1 
▲CD4+10 CD3+9 CD5+5 CD27+5 
▼MHCII-10 CD19-9 CD20-7 CD40-7 CD22-7 Igκ-5 Igλ-4 IgD-2 
SHP1-2 CD16-2 CD33-2 IgM-2 
3.4 
▲CD4+9 CD3+9 CD5+5 CD27+5 
▼MHCII-10 CD19-10 CD20-9 CD22-7 CD40-7 Igλ-3 Igκ-3 IgG-
2 CD33-2 CD16-2 SHP1-2 
3.5 
▲CD4+10 CD3+10 CD27+6 CD5+4 
▼MHCII-7 Igλ-5 CD20-5 CD19-5 CD22-5 CD40-4 IgD-3 IgM-3 
CD16-2 Igκ-2 CD79B-2 SHP1-2 
# Sample numbers match study numbers in Figure 4-11. 
§Unpublished data from AR Greenplate, prepared as in Leelatian et al.(Leelatian, Diggins et al. 2015) 
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Results 
 Four cytometry studies, Dataset A from Leelatian et al.(Leelatian, Diggins et al. 2015), Dataset B from 
Bendall et al.(Bendall, Simonds et al. 2011), Dataset C from Becher et al.(Becher, Schlitzer et al. 2014), and 
Dataset D containing unpublished human glioma data(Leelatian, Doxie et al. 2016) were used to evaluate MEM 
and identify biological features of expert and machine identified cell subsets.  These datasets had been 
previously analyzed by experts and by computational tools including viSNE(Amir el, Davis et al. 2013) and 
SPADE(Qiu, Simonds et al. 2011), which are respectively used in mass cytometry for dimensionality reduction 
and cell clustering(Diggins, Ferrell et al. 2015).   
Dataset A was mass cytometry data quantifying expression of 25 proteins on healthy human peripheral 
blood mononuclear cells (PBMC)(Leelatian, Diggins et al. 2015).  This dataset was chosen for two reasons: 1) 
the 7 cell subsets present are well-established and phenotypically distinct populations that served as a gold 
standard of biological ‘truth’ and 2) the cells in each of the 7 subsets had been characterized for 25 proteins that 
displayed varying homogeneous and heterogeneous expression patterns across the subsets.  Populations were 
expert gated following viSNE reduction to a two-dimensional view and each population was compared to the 
other cells in the sample as reference (Figure 4-2).  MEM returned automatic labels that matched prior expert 
analysis(Leelatian, Diggins et al. 2015) and correctly assigned high positive enrichment values to canonical 
protein features of each subset (Figure 4-2b), including CD4 on CD4+ T cells (▲CD4+6 CD3+5 ▼CD8a-4 CD16-
3), IgM on IgM+ B cells (▲MHC II+8 IgM+6 CD19+5 ▼CD4-6 CD3-5), CD11c and MHC II on monocytes 
(▲CD11c+8 CD33+7 CD14+6 CD61+6 MHC II+4 CD44+3 ▼CD3-5 CD4-4), and CD16 on NK cells (▲CD16+9 
CD56+2 CD11c+2 ▼CD4-7 CD3-4 CD44-3).  Proteins that were not significantly enriched in any of the 7 subsets 
of mature human blood mononuclear cells were correctly assigned near-zero MEM scores (e.g. CD34 and 
CD117 proteins normally expressed on hematopoietic stem cells, Figure 4-2b).  Similarly, proteins with little 
variability across cell subsets were assigned low, near-zero MEM scores, even for the proteins with the highest 
median expression values (e.g. CD45 on all subsets or CD45RA on non-T cell subsets Figure 4-2b).   
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Figure 4-2: Marker enrichment modeling (MEM) automatically labels human blood cell populations in Dataset A. a) 
Cells from normal human blood were previously grouped into 7 canonical populations using viSNE analysis and expert 
review of 25D mass cytometry data(Leelatian, Diggins et al. 2015).  b)  MEM labels were computationally generated for 
each canonical cell subset using the other six populations as reference.  The population labeled by immunologists as “CD4+ 
T cells” was labeled by MEM as ▲CD4+6 CD3+5 ▼CD8a-4 CD16-3 and comprised 48.72% of PBMC in this sample.  In 
contrast, the MEM label ▲CD16+9 CD56+2 CD11c+2▼CD4-7 CD3-4 CD44-3 was generated for the population gated as “NK 
cells”.  Heatmaps show protein enrichment values used to calculate MEM labels and median protein expression values for 
each protein on each cell subset.  Variability in protein expression across the 7 canonical cell populations is shown below 
to highlight proteins that were expressed homogeneously (low variability, e.g. CD45) and those that were expressed 
heterogeneously (high variability, e.g. CD8a, CD4). c) Graphs show decreasing f-measure (clustering accuracy) as markers 
were excluded from k-means cluster analysis based on high to low absolute MEM or median values, compared to random 
exclusion. 
 
Proteins enriched in a cell subset but rarely expressed on cells in the reference population were assigned 
positive MEM scores (e.g. CD19 on B cells, CD16 on NK cells, Figure 4-2b).  Negative enrichment scores 
occurred when proteins were commonly expressed in the reference population but consistently lacking on a 
specific cell subset.  For example, CD3 was expressed in a majority of the cells (CD4+ and CD8+ T cells 
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comprised 48.72% and 16.83% of the sample, respectively), thus B cells, NK cells, and monocytes were all 
assigned negative MEM scores for CD3 (Figure 4-2b).  Similarly, CD44 was assigned a negative MEM score for 
NK cells because all other cells in human blood expressed more CD44 per-cell (Figure 4-2b).  Thus, negative 
MEM scores highlighted a specific lack of expression, or negative enrichment, of a protein on a cell subset 
relative to the rest of the cells within the sample.  
In flow cytometry, differences in protein expression between two cell populations are routinely 
approximated by comparing median signal intensity.  This standard comparison of median signal intensity is 
equal to the “magnitude difference” portion of the MEM calculation (MAGDIFF = MAGPOP – MAGREF).  To compare 
MEM to this standard, MAGDIFF and MEM values were calculated for each of the 7 major immune cell populations 
shown in Figure 4-2 and their corresponding reference populations (Table 4-2).   
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Table 4-2. MEM equation components for PBMC subsets in Fig. 4-2 
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MAGPOP 4.3 2.3 3.2 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 2.4 3.1 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 
MAGREF 4.0 2.6 2.6 0.1 0.0 0.0 0.8 0.1 0.0 0.4 0.0 0.0 0.2 0.1 0.0 0.8 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 
IQRPOP 0.7 1.7 0.9 0.5 0.5 0.5 0.8 0.5 0.5 0.5 0.5 0.5 0.5 0.9 0.6 0.8 0.5 0.5 0.5 0.5 0.6 0.5 0.5 0.5 
IQRREF 0.8 1.1 1.6 2.3 0.5 0.5 4.8 2.2 0.7 1.2 0.5 0.8 3.7 1.8 0.6 1.2 1.4 0.5 0.7 0.5 0.5 0.5 0.5 0.5 
MEM 0.6 0.1 1.9 -5.0 0.0 0.0 -7.4 -4.7 0.7 -2.5 0.0 0.7 -8.8 4.2 4.1 -1.0 -2.7 0.0 -0.8 0.0 0.0 0.0 0.0 0.0 
MAGDIFF-S 0.5 -0.6 1.3 -0.2 0 0 -0.5 -0.2 0 -0.7 0 0 -0.4 4.8 6.4 -0.4 -0.6 0 -0.2 0 0.2 0 0 0 
MAGDIFF 0.3 -0.3 0.6 -0.1 0.0 0.0 -0.3 -0.1 0.0 -0.4 0.0 0.0 -0.2 2.3 3.0 -0.2 -0.3 0.0 -0.1 0.0 0.1 0.0 0.0 0.0 
IQRDIFF -0.1 0.7 -0.7 -1.8 0.0 0.0 -4.1 -1.7 -0.2 -0.7 0.0 -0.3 -3.2 -0.8 0.0 -0.4 -0.9 0.0 -0.2 0.0 0.1 0.0 0.0 0.0 
C
D
8
 T
 c
e
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MAGPOP 4.1 2.7 2.6 0.0 0.0 0.0 5.1 0.0 0.0 0.2 0.0 0.0 0.0 2.2 0.1 0.2 1.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
MAGREF 4.2 2.4 3.1 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.0 1.7 2.6 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
IQRPOP 0.7 1.0 0.8 0.5 0.5 0.5 0.5 0.5 0.5 0.6 0.5 0.5 0.5 0.8 0.5 0.6 0.8 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
IQRREF 0.7 1.4 1.3 0.9 0.5 0.5 0.9 0.7 0.5 0.6 0.5 0.5 0.6 2.5 3.0 1.0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
MEM -0.2 0.9 -1.3 1.0 0.0 0.0 7.3 0.5 0.0 0.3 0.0 0.0 0.3 3.5 -10.0 -1.7 1.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
MAGDIFF-S -0.2 0.5 -0.9 0 0 0 10 0 0 0.2 0 0 0 1.1 -5.3 -1 3.5 0 0 0.1 0 0 0 0 
MAGDIFF -0.1 0.3 -0.5 0.0 0.0 0.0 4.7 0.0 0.0 0.1 0.0 0.0 0.0 0.5 -2.5 -0.5 1.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
IQRDIFF -0.1 -0.4 -0.5 -0.4 0.0 0.0 -0.4 -0.2 0.0 -0.1 0.0 0.0 -0.1 -1.7 -2.5 -0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
MAGPOP 3.9 3.0 3.4 2.7 0.0 0.0 0.1 3.1 0.9 0.0 0.1 0.3 1.3 0.0 0.7 0.7 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 
D
C
s
 
MAGREF 4.1 2.5 3.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 1.9 2.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
IQRPOP 1.1 1.6 1.0 2.0 0.5 0.5 0.5 3.9 1.7 0.5 0.5 1.5 3.9 0.5 1.4 1.2 0.5 2.3 0.5 0.5 0.5 0.5 0.5 0.5 
IQRREF 0.7 1.3 1.3 0.5 0.5 0.5 1.5 0.5 0.5 0.7 0.5 0.5 0.5 2.4 3.1 1.0 0.6 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
MEM 0.2 0.5 0.8 2.6 0.0 0.0 -3.2 3.0 0.2 -0.5 0.1 -0.5 0.5 -7.6 -3.4 -0.1 -0.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 
MAGDIFF-S -0.4 1.1 0.7 5.6 0 0 -1 6.6 1.8 -0.1 0.1 0.6 2.6 -3.9 -2.8 0.2 0 2.6 0 0 0 0 0 0 
MAGDIFF -0.2 0.5 0.4 2.7 0.0 0.0 -0.5 3.1 0.9 -0.1 0.1 0.3 1.3 -1.9 -1.3 0.1 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 
IQRDIFF 0.4 0.3 -0.2 1.5 0.0 0.0 -1.0 3.4 1.2 -0.2 0.0 1.0 3.4 -1.9 -1.7 0.2 -0.1 1.8 0.0 0.0 0.0 0.0 0.0 0.0 
MAGPOP 4.4 3.5 3.1 3.1 0.0 2.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 
Ig
M
- 
B
 c
e
lls
 
MAGREF 4.1 2.5 3.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 1.9 2.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
IQRPOP 0.8 1.4 1.0 1.3 0.5 0.7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1.0 0.5 0.5 0.5 0.6 0.5 0.5 0.5 0.5 
IQRREF 0.7 1.3 1.3 0.5 0.5 0.5 1.5 0.5 0.5 0.6 0.5 0.5 0.5 2.4 3.0 1.0 0.6 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
MEM 0.2 1.3 0.5 3.3 0.0 3.0 -3.3 0.0 0.1 -0.5 0.0 0.0 -0.1 -7.6 -9.4 0.1 -0.4 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
MAGDIFF-S 0.4 2.1 0.2 6.5 0 5.2 -1.1 0 0.1 -0.2 0 0 0 -3.9 -4.2 0.2 0 0 0 0.3 0 0 0 0 
MAGDIFF 0.2 1.0 0.1 3.1 0.0 2.5 -0.5 0.0 0.1 -0.1 0.0 0.0 0.0 -1.9 -2.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 
IQRDIFF 0.0 0.0 -0.3 0.8 0.0 0.2 -1.0 0.0 0.0 -0.1 0.0 0.0 0.0 -1.9 -2.5 0.0 -0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
MAGPOP 4.3 2.6 2.7 3.7 3.0 2.5 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
Ig
M
+
 B
 c
e
lls
 
MAGREF 4.1 2.5 3.0 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 2.0 2.3 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
IQRPOP 0.7 1.2 0.9 1.4 2.6 0.7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 1.1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
IQRREF 0.7 1.4 1.3 0.5 0.5 0.5 1.6 0.5 0.5 0.7 0.5 0.5 0.6 2.4 3.0 0.9 0.7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
MEM 0.4 0.5 -1.0 4.0 2.9 3.0 -3.6 0.0 0.1 -0.6 0.0 0.0 -0.3 -7.5 -9.6 0.2 -0.6 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
MAGDIFF-S 0.4 0.3 -0.7 7.7 6.3 5.2 -1.2 0 0.2 -0.2 0 0 0 -4 -4.8 0.5 0 0 0 0.2 0 0 0 0 
MAGDIFF 0.2 0.2 -0.3 3.7 3.0 2.5 -0.6 0.0 0.1 -0.1 0.0 0.0 0.0 -1.9 -2.3 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
IQRDIFF -0.1 -0.2 -0.4 0.9 2.1 0.2 -1.1 0.0 0.0 -0.2 0.0 0.0 -0.1 -1.9 -2.5 0.1 -0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
MAGPOP 4.1 2.3 4.2 2.1 0.0 0.0 0.2 3.6 3.5 2.7 2.9 2.9 0.1 0.0 1.1 1.3 0.2 0.4 0.1 0.0 0.0 0.1 0.0 0.0 
M
o
n
o
c
y
te
s
 
MAGREF 4.2 2.5 2.9 0.0 0.0 0.0 0.6 0.0 0.0 0.1 0.0 0.0 0.0 2.0 2.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
IQRPOP 0.7 1.1 0.7 1.5 0.5 0.5 0.5 0.8 0.6 0.7 0.7 1.2 0.5 0.5 0.9 0.8 0.6 0.8 0.5 0.5 0.5 0.5 0.5 0.5 
IQRREF 0.7 1.4 1.2 0.5 0.5 0.5 1.7 0.5 0.5 0.5 0.5 0.5 0.6 2.2 3.1 0.9 0.6 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
MEM -0.2 -0.5 2.6 1.9 0.0 0.0 -3.5 4.3 4.5 3.1 3.5 3.1 0.2 -7.2 -5.0 1.1 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.0 
MAGDIFF-S -0.2 -0.3 2.6 4.4 0 0 -0.9 7.5 7.4 5.5 6 6.1 0 -4.2 -2.7 1.5 0.4 0.7 0.1 0 0 0.1 0 0 
MAGDIFF -0.1 -0.2 1.3 2.1 0.0 0.0 -0.5 3.6 3.5 2.6 2.9 2.9 0.0 -2.0 -1.3 0.8 0.2 0.4 0.1 0.0 0.0 0.1 0.0 0.0 
IQRDIFF 0.0 -0.2 -0.5 1.0 0.0 0.0 -1.1 0.3 0.1 0.2 0.2 0.7 -0.1 -1.7 -2.2 -0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 
MAGPOP 3.8 2.6 1.6 0.0 0.0 0.0 0.5 0.8 0.0 0.6 0.0 0.0 4.3 0.0 0.0 1.1 0.1 0.0 0.8 0.0 0.0 0.0 0.0 0.0 
N
K
 c
e
lls
 
MAGREF 4.2 2.4 3.2 0.0 0.0 0.0 0.5 0.0 0.0 0.1 0.0 0.0 0.0 2.1 2.6 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
IQRPOP 0.7 0.9 0.9 0.5 0.5 0.5 2.4 1.6 0.5 0.9 0.5 0.5 0.8 0.5 0.5 1.3 0.5 0.5 1.0 0.5 0.5 0.5 0.5 0.5 
IQRREF 0.7 1.5 1.0 1.0 0.5 0.5 1.3 0.5 0.5 0.5 0.5 0.5 0.5 1.6 2.8 0.9 0.7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
MEM -0.6 1.0 -2.3 1.2 0.0 0.0 0.6 0.1 0.0 0.1 0.0 0.0 5.2 -5.6 -9.6 0.3 0.5 0.0 0.4 0.0 0.0 0.0 0.0 0.0 
MAGDIFF-S -0.9 0.2 -3.3 0 0 0 0 1.6 0 1 0 0 9.1 -4.3 -5.3 1.1 0 0 1.7 0 0 0 0 0 
MAGDIFF -0.4 0.1 -1.6 0.0 0.0 0.0 0.0 0.8 0.0 0.5 0.0 0.0 4.3 -2.1 -2.5 0.5 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 
IQRDIFF 0.0 -0.6 -0.1 -0.5 0.0 0.0 1.1 1.1 0.0 0.4 0.0 0.0 0.3 -1.1 -2.3 0.4 -0.2 0.0 0.5 0.0 0.0 0.0 0.0 0.0 
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The MEM scores and magnitude difference values were most divergent for features that were negatively 
enriched on specific cell populations (Figure 4-3, Table 4-2). For example, the MEM score of CD8 on CD4+ T 
cells (CD4+ T cells: CD8-7) was lower than the difference in median CD8 expression between CD4+ T cells and 
the rest of the cells in the sample (CD4+ T cells: MAGDIFF CD8 = -0.3). MEM therefore emphasized the negative 
enrichment (i.e. lack of expression) of CD8 on these cells. Similarly, the MEM score for CD4 on most other 
populations (e.g. CD8- T cells: CD4-10) was lower than that population’s median difference (e.g. CD8+ T cells 
MAGDIFF CD4 = -2.0).  Thus, MEM correctly emphasizes the negative enrichment of CD4 on cells other than 
CD4+ T cells and APCs (Table 4-2). Incorporating information about feature variability therefore allows MEM to 
capture negative enrichment that is not reflected in magnitude difference alone (Figure 4-3 and Table 4-2). 
 
 
Figure 4-3. MEM captures negative feature enrichment that is not apparent in the difference between population 
medians. For 7 major normal human PBMC cell populations and 25 proteins, heatmaps show a) MEM scores; b) median 
expression levels (MAGpop); c) the difference between median expression value of the population and the median 
expression of the other immune cells (MAGdiff) (top) and the difference between the MEM score and the MAGdiff value to 
highlight differences between these two methods of population comparison (bottom); and d) the same comparisons made 
in c) using scaled MAGdiff values to -10 to +10 scale (linearly; x/max(MAGdiff)*10). Scaling is meant to allow for a more 
direct comparison to the MEM scores. 
 
To test the hypothesis that the features with the highest MEM scores would be important for 
computational cluster formation, the 25 proteins measured in Dataset A (Figure 4-2b) were sorted in six ways: 
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1) high to low MEM score, 2) high to low median value, 3) high to low MAGDIFF, 4) high to low z-score, 5) high to 
low K-S statistic, and 6) randomly (Table 4-3). Z-score and K-S statistic values are shown in Table 4-4. The 
proteins were then sequentially, cumulatively excluded from use in k-means clustering and F-measure was used 
to measure clustering accuracy (Fig. 4-2c and Figure 4-4). The order in which markers were excluded is shown 
in Table 4-3. Random exclusion was performed 15 times and the average result is shown (Fig. 4-2c). Clustering 
accuracy was most impacted by excluding proteins based on MEM score.  F-measure dropped to 0.75 after 
removing the proteins with the top 6 MEM scores, whereas this drop in f-measure was only seen after removing 
the 14 highest markers based on MAGDIFF, the 13 highest markers based on z-score, and the 12 highest markers 
based on K-S statistic values (Figure 4-4). Removing markers based on median value was not significantly 
different from removing markers randomly until after the 15 markers with the highest median signal intensity 
were excluded (Figure 4-4).   The same analysis was also performed with viSNE in place of k-means clustering 
to visualize the loss of population resolution when markers were excluded based on MEM or median scores (Fig. 
4-5c). In this case, loss of accuracy as markers were excluded by MEM values was reflected in the viSNE map 
as a loss of well-separated population islands comprised of one cell type. These results indicated that MEM 
enrichment scores captured the markers that were important to cell identity better than traditional comparisons 
based solely on median protein expression.  
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Table 4-3. K-S and z-score values for immune cell populations in Fig. 1 
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CD4+ T 1.8 1.2 3.3 9.7 4.1 3.8 2.7 2.2 1.8 2.0 2.0 0.1 2.3 3.8 2.5 3.7 1.3 3.4 3.2 1.7 3.6 6.7 1.2 3.7 3.6 
CD8+ T 1.0 1.2 1.3 6.2 10.0 6.5 3.5 1.1 1.0 1.4 1.0 0.7 1.5 2.3 1.2 8.3 0.1 1.9 2.8 3.3 2.1 4.1 0.8 2.0 0.3 
DC 0.8 0.7 4.5 4.0 3.1 1.5 0.3 3.1 5.8 2.6 1.8 0.2 4.7 4.8 2.8 1.8 0.6 3.4 1.8 0.9 2.1 6.7 0.9 7.8 0.8 
IgM- B 9.3 3.6 1.7 5.9 4.8 7.6 3.4 0.7 0.4 4.3 1.6 0.4 2.2 1.0 0.9 3.0 0.6 1.7 0.9 0.7 0.5 6.6 1.5 7.9 1.1 
IgM+ B 9.8 3.6 2.9 6.4 5.4 8.4 3.5 0.8 0.9 1.3 1.5 0.5 2.6 1.7 1.2 3.1 0.4 1.9 2.1 1.4 0.7 6.8 9.4 8.5 0.9 
Mono 0.9 0.5 9.8 4.9 3.0 2.5 1.2 9.2 5.6 1.0 0.8 1.5 9.9 9.4 9.7 2.7 1.4 1.7 6.6 4.2 2.5 7.3 0.6 8.2 1.8 
NK 1.8 1.4 3.6 6.6 1.9 2.0 1.6 1.1 0.9 1.5 3.2 0.6 1.3 4.7 1.1 1.0 1.8 9.8 7.3 2.7 2.8 7.7 2.0 3.2 6.1 
z
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CD4+ T -0.6 -0.3 -0.9 4.6 -0.7 -1.0 -0.6 -0.6 -0.5 -0.8 0.6 0.0 -0.7 -1.0 -0.7 -1.0 -0.3 -0.9 0.7 -0.4 1.6 1.9 -0.4 -0.9 -0.9 
CD8+ T -0.3 0.3 -0.1 -1.5 5.6 1.4 0.7 -0.4 -0.3 0.4 -0.2 -0.2 -0.5 -0.7 -0.5 4.2 0.0 -0.4 -0.4 -1.0 -0.5 0.9 -0.3 -0.5 0.1 
DC -0.1 -0.2 -0.9 -0.6 -0.8 -0.2 0.1 0.7 4.4 0.6 -0.4 0.0 1.1 1.9 0.2 -0.5 0.1 1.0 0.4 0.3 -0.5 -1.7 0.2 2.3 0.0 
IgM- B 4.4 1.2 -0.5 -1.6 -1.0 3.1 1.2 -0.2 0.0 1.2 0.4 0.1 0.0 -0.3 -0.3 -0.7 -0.1 -0.6 0.2 0.3 0.0 -1.6 -0.3 2.6 -0.3 
IgM+ B 7.6 1.4 -0.7 -1.7 -1.1 3.9 1.2 -0.3 0.1 0.5 0.5 0.2 0.0 -0.5 -0.4 -0.8 -0.1 -0.6 -0.3 0.4 -0.2 -1.7 9.9 3.8 -0.2 
Mono -0.3 0.1 5.1 -0.3 -0.8 -0.7 0.3 6.2 1.9 0.0 -0.2 0.5 8.7 5.1 10.0 0.1 0.4 -0.4 1.8 1.1 -0.6 -1.9 -0.3 2.3 0.0 
NK -0.4 -0.1 0.5 -1.9 -0.2 -0.6 -0.4 -0.4 -0.3 0.3 -1.0 -0.1 -0.5 0.8 -0.2 -0.2 0.5 7.4 -2.8 0.9 -0.7 -2.2 -0.5 -0.8 2.5 
Each population (POP) was compared to all non-population cells (REF). K-S statistic was calculated as a comparison 
between POP and REF distributions for each protein. Z-score was calculated as the number of standard deviations the POP 
mean was from the REF mean.  K-S and z-score were signed and scaled to -10 to +10 as for MEM values. 
 
Table 4-4. Order of marker exclusion for clustering and f-
measure (high to low) 
MEM MAG MAGDIFF z-score K-S  
CD4 CD8a CD8a CD8 CD14 
CD16 CD45 CD16 CD33 IgM 
CD3 CD16 CD11c CD16 CD33 
CD8a CD44 HLA-DR CD11b CD19 
CD11c CD11c CD33 CD19 CD16 
HLA-DR HLA-DR CD4 CD14 CD61 
CD33 CD33 CD61 CD4 CD8 
CD61 CD4 CD14 CD11c CD11b 
CD14 CD61 CD19 IgM CD11c 
CD19 CD45RA CD11b CD61 CD4 
CD11b CD14 IgM HLADR CD123 
CD69 CD11b CD3 CD20 CD69 
CD44 CD19 CD20 CD69 CD20 
CD20 IgM CD69 CD3 HLADR 
IgM CD3 CD44 CD44 CD44 
CD38 CD20 CD56 CD56 CD56 
CD45RA CD69 CD38 CD123 CD3 
CD56 CD38 CD123 CD45RA CD25 
CD45 CD56 CD45 CD38 CD117 
CD34 CD123 CD45RA CD25 CD34 
CD10 CD34 CD34 CD117 CD45RA 
CD117 CD25 CD25 CD34 CD38 
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CD123 CD10 CD10 CD45 CD45 
CD25 CD117 CD15 CD15 CD15 
CD15 CD15 CD117 CD10 CD10 
 
 
 
 
 
Figure 4-4. MEM highly scores markers that are important to clustering accuracy. Markers were sequentially and 
cumulatively excluded from k-means cluster analysis of Dataset A, from high to low, sorted based on 5 different statistics 
or scores (marker order shown in Table 4-3): MEM, median, median difference (MAGDIFF), z-score, and Kolmogorov-
Smirnov (K-S) statistic. Clustering accuracy was quantified as the f-measure where true cluster identity was assumed to 
be the clusters formed by clustering on all 25 markers in the dataset. The moving average of the f-measure is shown. 
Error bars represent the standard error. The vertical red line indicates the number of excluded features at which the f-
measure reached 0.75. 
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Figure 4-5. MEM highly scores markers that are important to viSNE mapping a) viSNE map for healthy human blood, 
built using 25 surface protein markers. Populations were identified by expert analysis and color coded. b). Top to bottom, 
left to right: viSNE maps generated as markers were iteratively, cumulatively excluded based on their MEM scores (high 
to low absolute value). Heat intensity for each cell indicates CD8 expression. c) Top to bottom, left to right: viSNE maps 
generated as markers were iteratively, cumulatively excluded based on their median scores (high to low absolute value). 
Heat intensity for each cell indicates CD8 expression. 
 
 Dataset B was mass cytometry data quantifying expression of 31 proteins on healthy human bone 
marrow(Bendall, Simonds et al. 2011). The diverse cell types identified in this dataset included mature cells, 
such as CD4+ T cells recirculating from blood, and cells developing along a continuum originating from 
hematopoietic stem cells (HSCs), such as myeloid and lymphoid cells.  Computational and expert analysis by 
the authors had previously identified 23 populations of cells(Bendall, Simonds et al. 2011) that were analyzed 
here by MEM (Figure 4-6a).  MEM effectively quantified enrichment of proteins marking stem and progenitor 
cells as well as mature cells.  For example, the cell subset labeled by Bendall et al. as HSCs was highly enriched 
for CD34 (CD34+6) and negatively enriched for CD45 (CD45-5), consistent with the authors’ original 
interpretation and longstanding biological observations(Civin, Strauss et al. 1984, Doulatov, Notta et al. 2012).  
As cells matured, MEM enrichment scores for HLA-DR, CD19, and CD3, three proteins functionally involved in 
shaping cell identity, increased on respective subsets of APCs, B cells, and T cells (Figure 4-6). Notably, MEM 
scores for CD45 expression in Dataset B varied across subsets and correlated with differentiation and maturation 
(Figure 4-6).  This result in bone marrow contrasted with the results in Dataset A, where MEM scores for CD45 
were uniformly near zero because the mature blood cell subsets all expressed high levels of CD45 (Figure 4-2).  
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Figure 4-6: MEM labels report enriched protein expression in human bone marrow cells in Dataset B.  a) Cells 
from normal human bone marrow were previously grouped into 23 nucleated cell populations using spanning-tree 
progression analysis of density normalized events (SPADE) and expert review of 31D mass cytometry data(Bendall, 
Simonds et al. 2011).  MEM labels are shown for 8 cell subsets that ranged in frequency from 0.002% to 10.57% of total 
cells. All non-population cells were used as reference for MEM.  Previously determined expert labels are included in 
parenthesis for comparison to automatically generated MEM labels.  Additional MEM analysis of this dataset is available 
for all 28 identified populations (Figure 4-14) and using stem cells as a common comparison point (Figure 4-5).  b) 
Pairwise analysis of the same dataset compared just bone marrow T cells (red) and B cells (blue).  The percentage of 
each population in the comparison is indicated in the lower right of the MEM label. 
 
 To assess how MEM scores captured intra-population variability, closely related populations from human 
bone marrow were grouped and new MEM labels calculated in a pairwise comparison of CD19+ B cells and CD3+ 
T cells (Dataset B, Fig. 4-6b). As expected, CD3+ T cells had a lower MEM score for CD8 than the subset of 
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CD3+ CD8+ T cells (CD8+3 vs. CD8+8, respectively) because CD8- CD4+ T cells were part of the parental CD3+ 
T cell population.  Likewise, IgM enrichment was lower in all CD19+ B cells than in the IgM+ subset of CD19+ B 
cells (IgM+3 vs. IgM+6).  As a general rule, MEM scores will approach median values as feature variability within 
populations decreases (Figure 4-7).  Thus, MEM captures feature enrichment and heterogeneity better than 
median in diverse populations, as in Fig. 4-2c. 
 
 
 
Figure 4-7. MEM scores largely reflect median expression values for relatively homogenous populations. 
Heatmaps show median intensity of protein expression (left) and protein enrichment by MEM (right) for measured proteins 
in 28 populations characterized as relatively homogeneous for established cell types by expert analysis (rows).  Each 
population was compared to the other 27 subsets for the MEM analysis.  MEM scores approach median expression 
values in homogeneous populations because the contribution of variance approaches zero. 
 
 
 Dataset C was mass cytometry data quantifying expression of 38 proteins on murine cells from eight 
tissues(Becher, Schlitzer et al. 2014).  This dataset was chosen to evaluate MEM population comparisons across 
tissues in a non-human model and to test the hypothesis that MEM would objectively identify the most enriched 
features of novel cell subsets.  Dataset C was analyzed three different ways by MEM: 1) comprehensive MEM 
phenotyping highlighted the major features of each population, as in Becher et al. (Figure 4-8); 2) subset-focused 
MEM phenotyping identified the distinguishing features of novel cell subsets identified by Becher et al., such as 
innate lymphoid cell (ILC) population 28 (Figure 4-9 and Figure 4-10); 3) tissue-specific MEM phenotyping 
provided a new way of highlighting how neutrophil phenotype varied across tissues.  While comprehensive 
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phenotyping provided an overview of the major differences between cell subsets (Figure 4-8), subset-focused 
phenotyping better captured the features experts had identified as uniquely enriched on novel cell populations 
(Figure 4-9).  For example, cluster 28 was a novel population identified by Becher et al. as CD11bint NK 
cells(Becher, Schlitzer et al. 2014).  The MEM label for cluster 28 within ILCs was ▲CD11b+5 CD62L+3 ▼CD4-
7 CD103-4 Terr119-3 (Figure 4-9b and Figure 4-10).  This MEM label captured the key feature of this novel 
innate lymphoid cell subset (CD11bint) and highlighted additional features that can be used to match this subset 
to cells identified by others (i.e., to cytotype the population).   
 
 
 
 
 
Figure 4-8. MEM quantifies feature enrichment on 28 automatically identified murine myeloid cell subsets. MEM 
labels are shown for each of 28 murine myeloid populations automatically identified by Becher, et al(Becher, Schlitzer et 
al. 2014). Each population was compared to the remaining 27 populations as reference for the MEM calculation. 
 
 To compare tissue specific phenotypes, MEM was next used in a novel analysis characterizing 
neutrophils from each of the 8 tissues (Figure 4-9c). CD54 (ICAM-1), was highly enriched on lung neutrophils 
(CD54+8) as opposed to on neutrophils from other tissues, such as bone marrow (CD54-3). CD54 plays a 
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crucial role in neutrophil recruitment to the lungs(Basit, Reutershan et al. 2006). MEM also revealed that 
CD62L, a molecule that is shed from neutrophils that have recently left the bone marrow, was most enriched 
on bone marrow neutrophils(Furze and Rankin 2008). Other markers, including CD24, HLA-DR, and CD48, 
also displayed tissue-specific enrichment on neutrophils.  Therefore, changing the context of the MEM 
comparison and using alternative reference populations can reveal enrichment of biologically relevant features 
that is not apparent with standard approaches, such as median analysis. MEM comparisons can also capture 
the environment in which a subset is normally found, and this was observed to provide additional information 
about the tissue context that might be especially helpful in translational applications of MEM in disease 
settings.  These results indicate that MEM labels complement unbiased population discovery and effectively 
characterize cyto incognito(Irish 2014) by providing unbiased descriptions that correctly capture key features of 
novel cell types. 
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Figure 4-9. MEM labels characterize subset specific and tissue specific phenotypes of murine innate lymphoid 
cells and neutrophils in Dataset C.  a) Previous computational analysis automatically grouped murine cells into 28 
populations using t-SNE and DensVM analysis of 38 proteins measured by mass cytometry(Becher, Schlitzer et al. 2014).  
b)  Density of each of 6 computationally defined populations of ILCs is overlaid in color on a greyscale contour plot of cell 
density for all ILCs (red region from a).  MEM labels characterized the enriched features of each computationally identified 
population, such as ILC subset 28, which was distinguished as CD11b+5. c) MEM labels were generated for all neutrophil 
subsets according to tissue site (labeled in blue).  Density of each neutrophil population is overlaid in color on a contour t-
SNE plot of all neutrophils (blue region in a).  The percentage of each population in the comparison is indicated in the 
lower left of the MEM label. Additional MEM analysis of this dataset is available for all 28 identified populations (Figure 4-
8).   
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Figure 4-10. Focused MEM analysis quantifies feature enrichment within phenotypically similar groups of cells a-
f) Focused MEM analysis on murine myeloid cell subsets. A MEM label for one population within each group is shown as 
an example. Groups were defined as the 6 major murine subgroups identified by t-SNE and DensVM by Becher et 
al.(Becher, Schlitzer et al. 2014). 
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An important aspect of MEM is generation of machine-readable quantitative labels that can be used to 
register population identities across samples and studies.  A MEM label for a newly discovered population can 
be compared quantitatively against a reference set of established MEM labels or a MEM label reported in a 
paper.  To illustrate this idea, pairwise similarity of MEM scores was calculated for 80 populations of cells from 
7 different studies including healthy CD4+ T cell and B cell (Figure 4-11).  Cells had highly similar MEM scores 
within each major cell type, regardless of platform (mass vs fluorescence flow cytometry), study, or tissue source.  
For example, T cells run on mass cytometry from different blood donors were 97% ± 1.3 similar to each other, 
85% ± 1.9 similar to T cells from blood run on fluorescence flow cytometry, and 87% ± 2.1 similar to T cells from 
tonsil run on mass cytometry (Figure 4-11).  However, these cells were 66.9% ± 13 similar to any B cell 
population. This indicates that MEM scores provide a way to communicate cell identity and to quantify similarities 
of cell types from the text label alone.   
Dataset D included 52 populations of tumor infiltrating APCs, tumor infiltrating T cells, and non-immune 
malignant tumor cells identified in human glioma tumors(Leelatian, Doxie et al. 2016).  To obtain these 
populations, each tumor was analyzed by viSNE and cell subsets were expert gated solely on t-SNE cluster 
density (Figure 4-12).  To determine whether MEM could distinguish immune cell subsets from other tumor cell 
types with limited information, MEM scores were calculated using only 9 markers (S100B, TUJ1, GFAP, Nestin, 
MET, PDGFRα,EGFR, HLA-DR, and CD44) that were expected to be expressed on cancer cells (Figure 4-13a).  
The 52 populations were grouped into 13 major groups of cell types based on MEM enrichment of the 9 analyzed 
proteins and these groups interpreted as either tumor infiltrating APCs (Figure 4-13b, blue), tumor infiltrating T 
cells (Figure 4-13b, green), or non-immune tumor cells (Figure 4-13b, red).  To confirm cell identity, four protein 
features that had been excluded from MEM analysis were assessed (Figure 4-13c, CD45, CD3, CD45RO, and 
CD64). CD45 and CD3 were used to confirm T cell identity and CD45 and CD64 were used to confirm APC 
identity. MEM correctly identified both immune cell subsets from all tumor types without using key immune 
lineage markers and without using healthy populations (e.g. APCs from blood or tonsil) to guide the clustering.  
Thus, MEM labels distinguished populations of cells based on non-traditional features and in a disease context.  
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Figure 4-11. Classification based solely on MEM label groups samples of T cells and B cells measured in diverse 
studies using different cytometry platforms. A) MEM label values were compared for each of 80 populations (CD4+ T 
cells and B cells) from 3 human tissues representing 6 mass cytometry studies and 1 fluorescence flow cytometry study.  
The similarity score for two populations was 100% when MEM label exponents were identical for all of the shared 
proteins.  Populations are shown clustered according to MEM label percent similarity.  Tissue type, source study, and 
individual sample IDs are indicated to the right. Published study references: Study references: 1) Nicholas KJ, et al., 
Cytometry A 2016(Nicholas, Greenplate et al. 2016); 2) Polikowsky et al., J Immunol. 2015(Polikowsky, Wogsland et al. 
2015); 3) Ferrell et al., PLOS One 2016(Ferrell, Diggins et al. 2016); 4) Amir et al., Nature Biotech 2013(Amir el, Davis et 
al. 2013); 5) Bendall et al., Science 2011(Bendall, Simonds et al. 2011); 6) unpublished data courtesy of Greenplate AR, 
Irish lab;  7) Leelatian et al., Methods Mol Bio 2015(Leelatian, Diggins et al. 2015).  *indicates samples stimulated by 
bacterial superantigen Staphlococcus enterotoxin B(Nicholas, Greenplate et al. 2016). B) Representative MEM labels for 
CD4+ T cells (top) and B cells (bottom) from SEB-stimulated normal human blood run on mass cytometry (1.4, top), 
normal human bone marrow run on mass cytometry (5), normal human tonsil run on mass cytometry (2.5), SEB-
stimulated normal human blood run on fluorescence flow cytometry (1.4, bottom), and a second analysis of normal human 
blood run on mass cytometry (6.1).  
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Figure 4-12. Unsupervised clustering and gating of 52 populations of malignant and immune cells in glioma. Live 
nucleated immune and malignant cells were gated from glioma tumors as described in Leelatian and Doxie et al., 
Cytometry B 2016(Leelatian, Doxie et al. 2016).  Patient-specific t-SNE axes were created in separate viSNE analyses of 
each tumor (e.g. t-SNE1-G-08 for glioma tumor G-08).  Shown here is density of cells on t-SNE1 vs. t-SNE2 from each 
tumor-specific viSNE analysis.  Expert analysis of density was then used to identify 52 cell clusters from the 4 glioma 
tumors.  These 52 populations were subsequently grouped by MEM in Fig. 4-13a using 9 proteins expressed on 
malignant cells. 
 
 
Figure 4-13. MEM correctly grouped immune and cancer cell populations from glioma tumors using nine proteins 
expressed on cancer cells. (A) A heatmap of MEM enrichment scores is shown for 52 populations of cells identified in 
tumors from 4 glioblastoma patients (G-08, G-10, G-11, G22) in an unsupervised manner using viSNE.  MEM scores were 
then calculated based only on the nine measured proteins expected to be expressed on cancer cells (S100B, TJF1, 
GFAP, Nestin, MET, PGFRα, HLA-DR, and CD44).  (B) Each population was annotated for a cell type based on review of 
the MEM label and classified as tumor infiltrating APCs (blue), tumor infiltrating T cells (green), or non-immune tumor cells 
(red).  (C) A heatmap of median intensity values is shown for the 13 measured proteins from each of the 52 tumor cell 
populations.  Expression of CD45, CD3, and CD64 was used to assess the respective identity of leukocytes, T cells, and 
antigen presenting cells. 
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Figure 4-14. Using stem cells as reference population reveals high enrichment of maturation and differentiation 
markers on bone marrow cell subsets. Clustered heatmap of MEM scores from analysis using HSCs as the reference 
population for the bone marrow cell subsets identified by Bendall et al.(Bendall, Simonds et al. 2011)  Comparison to stem 
cells as a common reference point provided intuitive MEM scores. 
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Figure 4-15. MEM labels reveal potentiated signaling in acute myeloid leukemia blasts from patients with poor 
chemotherapy responses. a) Previous analysis(Irish, Hovland et al. 2004) used median analysis of 2-color fluorescence 
cytometry and 3 staining panels to measure 6 phospho-protein responses to 6 stimulation conditions in leukemia blasts 
from 30 patients.  The new heatmap here shows clustering of MEM scores for each patient compared to the other AML 
patients.  Clustering on MEM enrichment scores identified the same four groups of patients as in the original analysis of 
median signaling response. b) The four patient cluster groups were defined based on basal and potential signaling and 
termed signaling-cluster non-potentiated (SC-NP), potentiated basal (SC-PB), potentiated-1 (SC-P1), or potentiated-2 
(SC-P2), and SC-P2.  SC-P2 was identified as enriched for high risk clinical features. Clinical features for each patient are 
shown(Irish, Hovland et al. 2004).c) Individual patient MEM scores are shown for 6 representative patients of the 30 AML 
patients. 
 
  
87 
 
Discussion 
MEM provides a straightforward language for labeling cell types based on enriched features.  Given 
widespread adoption and reporting, MEM labels could be used to identify and communicate cytotype across 
studies and platforms in a manner analogous to the way cluster of differentiation (CD) naming was used to 
communicate newly identified antigen targets of antibodies(1984).  While it is useful in some cases to identify 
tissue-specific features of cell subsets, a more intuitive application of MEM compares populations against a 
common reference.  As an example, HSCs were used as a common reference for all other cell subsets (Figure 
4-11 and Figure 4-14).   
This technique of using HSCs as a common reference was used to compare cell population similarity 
across experimental platforms, scientific groups, and tissue of origin. CD4+ T cells were chosen due to the 
similarity in phenotype we might expect across tonsil, blood, and bone marrow, and it was striking that mass and 
fluorescence cytometry produced highly similar MEM labels (Table 4-1 and Figure 4-11). In contrast, SEB 
stimulated and unstimulated B cells measured by fluorescence cytometry had lower similarity scores (Figure 4-
11).  This arose because only 4 shared proteins were enriched on B cells measured by fluorescence cytometry, 
so the similarity scores were very sensitive to small changes in any one protein.  This observation highlights the 
value of measuring more markers, especially in the setting of unusual or unexpected cell phenotypes.  The more 
markers measured, the more chances for cells to be similar or different, and the more robust the MEM 
comparison. However, only 9 non-immune markers were needed to distinguish immune cells from cancer cells 
without including healthy immune cell markers to guide clustering (Figure 4-13).  Going forward, MEM can be 
used to guide feature selection for both computational and experimental analysis. 
Metrics like area under ROC curve (AUC), z-score, and K-S statistic quantify features of distributions that 
MEM does not capture, including difference or overlap, deviation, skew, and shape.  AUC, for example, 
characterizes degree of non-overlap between two distributions and has recently been shown to be superior to 
K-S testing for characterizing “percent positive” in flow cytometry data(Kim, Donnenberg et al. 2016).  Both K-S 
and AUC capture whether peaks are different.  In some cases, difference metrics may be useful for highlighting 
features that are not enriched but which have different distribution shapes in the POP and REF.  For example, 
bimodal vs. unimodal spreads with similar median and IQR values will score highly for K-S or AUC but have 
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near-zero MEM scores.  This matches expert interpretation as we would say that neither population is enriched 
for the feature even though the distributions have differing shapes.  MEM is set up as a scaled enrichment score 
so that it will be less sensitive to instrument variation and platform differences (as in Figure 4-11).  MEM is also 
able to quantify and weight negative enrichment, an important aspect of population identity that is not always 
captured by other comparative metrics, such as z-score.   
Other potential uses for MEM include clinical assessment of enriched features of patient response groups 
for the purpose of hypothesis generation and therapy development.  For example, in an AML phospho-flow 
dataset(Irish, Hovland et al. 2004), MEM revealed potentiated STAT1 phosphorylation following IFNγ in AML 
cells from one patient group (Figure 4-15).  IFNγ signaling via STAT1 activates expression of MHC and B7 family 
members including PD-L1, and potentiated signaling through this pathway might identify AML patients that could 
benefit from checkpoint inhibitor therapy(Loke and Allison 2003).  MEM can also be used to monitor changes in 
tissues over time during treatment.  Deviation from a stable MEM score for peripheral blood cell subsets would 
be expected in the case emerging malignant cells(Greenplate, Johnson et al. 2016), and lack of change towards 
a healthy set of MEM scores for blood or bone marrow cell subsets might indicate a lack of response to 
chemotherapy for a leukemia patient. Going forward, MEM is expected to assist in machine learning applications 
by providing quantitative text descriptions of cytotype that can be algorithmically parsed and used to classify 
newly identified cell subpopulations.   
Methods 
Data generation and acquisition 
The tonsil and normal human bone marrow data sets (Table 4-1, indicated by *, and Figure 4-11) were 
generated by CyTOF analysis as described by Leelatian, et al(Leelatian, Diggins et al. 2015).  
The normal human bone marrow data set from Bendall, et al(Bendall, Simonds et al. 2011) (Figure 4-6) 
was shared and downloaded from Cytobank as FCS files that included the cell population IDs defined by Bendall, 
et al(Bendall, Simonds et al. 2011). 
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The murine myeloid CyTOF dataset from Becher, et al(Becher, Schlitzer et al. 2014) (Figure 4-9) was 
shared and downloaded from Cytobank as FCS files that contained gated cell events and cluster IDs as 
designated by automated analysis in Becher et al, 2014(Becher, Schlitzer et al. 2014).  
The phospho-flow AML data set(Irish, Hovland et al. 2004) (Figure 4-15) was shared on Cytobank and 
downloaded as FCS files. 
The CyTOF datasets from analysis of human GBM, melanoma, and normal blood samples (Figure 4-13) 
was shared on Cytobank and downloaded as text files after viSNE analysis and gating. Data was previously 
analyzed and described in Leelatian et al, 2016(Leelatian, Doxie et al. 2016). 
CyTOF data pre-processing and analysis 
Data analysis was performed using the online analysis platform Cytobank(Kotecha, Krutzik et al. 2010) 
and the statistical programming environment R. Raw median intensity (MI) values were transformed to a 
hyperbolic arcsine scale. A cofactor of 15 was used for the PBMC dataset, and 5 was used for the normal human 
bone marrow data set and for the murine myeloid data set.  Single, intact cells were gated based on cell length 
(30-60) and nucleic acid intercalator (iridium). Major PBMC subsets were gated based on CD45 expression 
(leukocytes) and on canonical lineage marker expression to identify major blood cell subsets.  
FCS files were exported from Cytobank as FCS or tab-delimited text files that were parsed for expression 
intensity information in R(Team 2013). The R package flowCore was used to parse FCS files(Hahne, LeMeur et 
al. 2009). MEM was calculated using the arcsinh transformed MI values, as described above. Heatmaps were 
generated using the heatmap.2 function in the gplots package(Gregory R. Warnes 2015). 
Fluorescence Phospho-Flow AML Data Analysis 
 Data were downloaded from Cytobank as FCS files and processed in R as described above. MFI values 
were transformed to a log normal scale. For each AML patient, a median value and an IQR value was calculated 
for each marker in the unstimulated condition and for the stimulated conditions. The unstimulated median values 
were subtracted from the stimulated median values, and likewise for the IQR values. MEM was then calculated 
by comparing each patient’s subtracted median and IQR values to those of the other patients. This enabled a 
comparison of fold change signaling values rather than raw values. 
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Marker Enrichment Modeling (MEM) 
MEM equation 
The MEM equation is implemented as an R package. Currently, MEM uses medians as the magnitude value; 
however, depending on the data type, mean may be a more appropriate magnitude statistic and mean could be 
substituted for median in the equation. Similarly, other statistics, such as variance, might be substituted for IQR.  
The MEM equation was developed with the intention of capturing and quantifying population-specific feature 
enrichment in a simple equation that avoids over-fitting or unnecessary computation. The primary goal of this 
equation is to scale magnitude differences depending on distribution spread. While other distribution features 
such as skew or shape could be informative, incorporating only two pieces of information – magnitude and 
spread – into the equation captured enough information to be useful in quantifying both positive and negative 
population-specific feature enrichment. 
MEM output and score scaling 
The MEM R script outputs a heatmap of MEM values with a natural language summary of feature 
enrichment as the population (row) names. The + or - value provided along with the marker name is converted 
to a -10 to +10 scale and rounded to the nearest integer. As implemented here, the maximum of the scale was 
set using the highest absolute value MEM score observed across all markers and populations.  All values in the 
matrix are divided by this maximum value and multiplied by 10 to achieve the -10 to +10 scaling. After scaling, 
the original sign value is reapplied to each MEM score. Scaling the output this way is intended to generate MEM 
values and labels that are intuitive to human readers and to facilitate comparison of feature enrichment across 
experiments, samples, batches, time points, and data types.   
IQR Threshold 
Because MEM uses a ratio of IQR values, near zero values in the denominator, IQRPOP, will greatly 
increase MEM scores.  For each measurement type, it is important to identify a minimum significant IQR value 
so that small IQR values below the platform’s ability to distinguish signal from noise do not inappropriately 
increase MEM scores. To automatically determine a minimum threshold for IQRPOP, the algorithm here calculated 
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the average of the IQR values that were associated with the lowest quartile of population and reference medians.  
For the mass and fluorescence cytometry datasets used, the automatically calculated IQR threshold was on 
average 0.5 ± X and so the IQR threshold for all studies here was set to 0.5.   The default IQR threshold in the 
algorithm is also set to 0.5.  To have the IQR threshold re-calculated, investigators should specify the “auto” 
option for the IQR.thresh argument in the MEM function.  It is recommended that investigators applying MEM to 
datasets from different instruments or who are testing MEM for the first time determine whether a change in the 
IQR threshold is needed. 
Reference population selection 
MEM score are contextual in that a population’s MEM score depends on the reference population(s) to which it 
is compared. Selection of a reference population should be made deliberately depending on the biological 
question being addressed. When populations in a MEM analysis arise from different experimental sources, it 
may be necessary in some cases to normalize measurements prior to MEM analysis to avoid artifacts from 
experimental variation. 
PBMC processing and mass cytometry  
 Peripheral blood mononuclear cells (PBMC) were isolated and cryopreserved as in Greenplate, et 
al(Greenplate, Johnson et al. 2016). PBMC were stained with metal conjugated antibodies and prepared for the 
mass cytometry as previously described(Greenplate, Johnson et al. 2016).  The following antibodies were used 
in the staining panel: CD19-142, CCR5-144, CD4-145, CD64-146, CD20-147, CCR4-149, CD43-150, CD14-
151, TCRγδ-152, CD45RA-153, CD45-154, CXCR3-156, CD33-158, CCR7-159, CD28-169, CD29-162, 
CD45RO-164, CD16-165, CD44-166, CD27-167, CD8-168, CD25-169, CD3-170, CD57-172, PD-L1-175, and 
CD56-176 (Fluidigm Sciences). In addition, the following purified antibodies from Biolegend were labeled using 
MaxPar DN3 kits (Fludigm Sciences), stored at 4°C in antibody stabilization buffer (Candor Bioscience GmbH) 
and used in the same panel: ICOS-141, TIM-143, CD38-148, CD32-161, HLA-DR-163, CXCR5-171, and PD-1-
174.  
Cell subpopulation MEM Score Similarity Calculations 
Comparison of CD4+ T cells to B cells 
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In order to assess the robustness of MEM across tissue sample types, donors, experimental runs, and flow 
cytometry platforms (fluorescence and mass cytometry), MEM scores were calculated for cell subsets from 7 
different experiments that included 3 healthy human bone marrow samples(Bendall, Simonds et al. 2011, Amir 
el, Davis et al. 2013, Ferrell, Diggins et al. 2016), 9 healthy human PBMC samples(Leelatian, Diggins et al. 2015, 
Nicholas, Greenplate et al. 2016), and 6 healthy human tonsil samples(Polikowsky, Wogsland et al. 2015). MEM 
scores were calculated for each population using as the reference population a combination of hematopoietic 
stem cells gated as CD34+ CD38lo/- from two studies of healthy human bone marrow(Bendall, Simonds et al. 
2011, Ferrell, Diggins et al. 2016).  Population similarity was calculated using root mean squared distance 
(RMSD) calculated on all population MEM scores in a pairwise fashion. MEM scores were calculated using all 
markers in common between each dataset and the HSC reference (Table 4-5).   
Table 4-5. Full antibody panels for immune cell datasets in Fig. 4 
Dataset Panel 
Nicholas KJ et 
al.(Nicholas, Greenplate et 
al. 2016) 
HLADR, CD8, CD25, CD38, CD4, CD3, CD62L, CD69 
Nicholas KJ et 
al.(Nicholas, Greenplate et 
al. 2016) 
HLADR, CD19, CD27, CD38, CD86, CD20 
Greenplate AR§ 
ICOS, CD19, TIM3, CCR5, CD4, CD64, CD20, CD38, CCR4, CD43, CD14, 
TCRγδ, CD45RA, CD45, CXCR3, CD33, CCR7, CD28, CD32, CD69, HLADR, 
CD45RO, CD16, CD44, CD27, CD8, CD2, CD3, CXCR5, CD57, PD1, PDL1, 
CD56 
Ferrell et al.(Ferrell, 
Diggins et al. 2016) 
CD235a, CD19, CD117, CD11b, CD4, CD64, CD7 , CD34, CD61, CD123, 
CD13, CD62L, CD45, CD183, CD33, CD11c, CD14, CD15, CD16, CD24, 
CD38, CD25, CD3, CD185, HLA-DR, CD184, CD56 
Leelatian et al.(Leelatian, 
Diggins et al. 2015) 
CD19, CD117, CD11b, CD4, CD8a, CD20, CD34, CD61, CD123, CD45RA, 
CD45, CD10, CD33, CD11c, CD14, CD69, CD15, CD16, CD44, CD38, CD25, 
CD3, IgM, HLADR, CD56 
Bendall et al.(Bendall, 
Simonds et al. 2011) 
CD45, CD45RA, CD235ab, CD19, CD11b, CD4, CD8, CD34, CD161, CD20, 
CD41, CD11c, CD123, IgM, CD10, CD33, CD14, CD38, CD15, CD16, CD44, 
CD7, CD13, CD56, CD61, CD117, CD47, HLADR, CD90, CXCR4, CD3 
Polikowsky et 
al.(Polikowsky, Wogsland 
et al. 2015) 
CD19, CD5, IgG, CD4, IgD, CD20, CD16, Igλ, CD45, CD27, CD86, CD33, 
CD22, Igκ, CD79B, CD40, CD44, CD38, CD8, CD3, IgM, HLADR, SHP1, CD56 
Amir et al.(Amir el, Davis 
et al. 2013) 
CD45, CD3, CD45RA, CD19, CD11b, CD4, CD8, CD34, CD20, Ki67, CD33, 
CD123, IκBα, CD38, CD90 
HSC REF:  
Amir et al.(Amir el, Davis 
et al. 2013)  
& Ferrell et al.(Ferrell, 
Diggins et al. 2016) 
CD45, CD45RA, CD235ab, CD19, CD11b, CD4, CD8, CD34, CD161, CD20, 
CD41, CD11c, CD123, IgM, CD10, CD33, CD14, CD38, CD15, CD16, CD44, 
CD7, CD13, CD56, CD61, CD117, CD47, HLADR, CD90, CXCR4 
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Note: MEM comparisons were made using all markers in common between each dataset and the HSCs (combined from 
Amir et al. and Ferrell et al. datasets). Pairwise RMSD comparisons of MEM scores were made using all markers in 
common between the pairs of datasets.  §Unpublished data from AR Greenplate, prepared as in Leelatian et al.(Leelatian, 
Diggins et al. 2015) 
 
RMSD was calculated here as the square root of the average in squared distance between all MEM values in 
common for each pair of populations (Table 4-4) and then converted into percent maximum possible RMSD.  
Given the -10 to 10 MEM scale, an RMSD of 20 was the maximum possible difference and corresponded to 0% 
similarity, whereas an RMSD of 0 between MEM labels indicated 100% similarity.  This approach emphasized 
differences in marker expression when comparing populations.  Calculated statistics for CD4+ T cell comparisons 
included average MEM value +/- standard deviation and p-value calculated using an unpaired Student’s t-test. 
Human Glioma and Normal Immune Cell MEM Analysis 
Glioblastoma data (G-08, G-10, G-11, and G-22) were collected following a published protocol(Leelatian, Doxie 
et al. 2016). Cells were stained with isotope-tagged antibodies to detect surface and intracellular targets following 
established protocols(Leelatian, Diggins et al. 2015, Leelatian, Doxie et al. 2016). MEM analysis of glioblastoma 
patient samples were performed with 9 markers (S100B, TUJ1, GFAP, Nestin, MET, PDGFRα, EGFR, HLA-DR, 
and CD44), using arcsinh transformation of original median intensity values with a cofactor of 5. Each cell subset 
was the POP, and the remaining cell subsets were the REF in the analysis. 
Z-score and K-S statistic calculations 
Z-score was calculated between POP and REF as (MEANpop-MEANref)/STDEVref for each marker. 
The K-S statistic was calculated comparing the distribution for each marker on POP and REF using the function 
ks.test() in R. 
F-measure Analysis 
PBMC populations were defined by expert human gating on canonical markers. For f-measure analysis 
(Figure 4-2c and Figure 4-5a), the 25 measured markers from the CyTOF analysis of healthy PBMC were sorted 
based on absolute MEM scores, median values, median difference (shown in Figure 4-5a), or randomly across 
all PBMC populations and the 25 measured proteins. The 5x25 matrix was converted into an ordered vector 
(length 25X5) and then sorted by absolute value. The first occurrence of each marker in the list was kept and 
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subsequent occurrences of that marker in the list (i.e. that marker’s scores on other populations) were discarded. 
The order of markers excluded by MEM, median, median difference, z-score, and K-S statistic are shown in 
Table 4-3.  Markers were then sequentially, cumulatively excluded from k-means clustering of cells from high to 
low absolute for each statistic or score. F-measure was calculated as:  
Sensitivity = True Positives/ (True Positives + False Negatives) 
Specificity = True Negatives/ (True Negatives + False Positives) 
F-measure = 2*(sensitivity*specificity)/ (sensitivity + specificity)  
An F-measure was calculated for each round of clustering, where truth was the cell cluster ID resulting 
from clustering on all 25 markers. The moving average of f-measure with an interval of 3 was calculated in 
Microsoft Excel. The f-measures for random marker exclusion are the average at each point of 15 different 
rounds of random marker exclusion from clustering.  
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CHAPTER 5  
 
 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
 
A single-cell level understanding of cancer cells and the microenvironment is essential for identifying, 
quantitatively describing, and tracking biologically and clinically relevant populations of cells. Advances in 
computational analysis tools and workflows enable single-cell level characterization of tissues in order to better 
understand human health and disease.   
This dissertation presents and demonstrates a modular analysis workflow that combines supervised and 
unsupervised computational analysis for automated population discovery and a comprehensive view of immune 
and AML cell phenotypes. The initial biaxial gating and dimensionality reduction allows the analyst to assess 
data quality and provides a complete overview of the data. However, grouping cells into subpopulations in the 
last steps of the workflow is completely automated, thereby providing a robust and repeatable analysis approach 
that can be scaled across large datasets and studies. Going forward, it will be beneficial to develop standardized, 
modular workflows that leverage the utilities of multiple computational tools in order to extract as much 
meaningful data as possible from these types of multi-dimensional data.  
The tools that have been developed for population identification, such as dimensionality reduction, can 
also also be used as the basis for novel quantitative analyses, as demonstrated in Chapter 3. This study 
highlighted the utility of mass cytometry and computational analysis tools for tracking changes in AML blast cell 
populations over time and after treatment. The use of viSNE analysis was shown to be an efficient means of 
tracking AML cell populations after treatment in order to determine which cells persisted after therapy. This 
analysis method revealed that these persister cells became less phenotypically stem-like following treatment. 
This finding was unexpected given that cancer stem cells have been shown to be responsible for relapse in AML 
and would therefore be expected to express surface proteins similarly to normal stem cells.    
Chapter 4 presents MEM, an automated method for quantifying feature enrichment, and demonstrates 
how this tool is able to identify proteins that are important to cell population identity in multiple datasets from 
analysis of immune cells and cancers. Markers known to be positively and negatively enriched on specific 
populations of human and murine immune cells from multiple tissue types were highlighted by MEM analysis. 
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MEM labels also were successfully used to group CD4+ T cells and B cells from different tissues, experiments, 
and platforms. The possibility of using MEM labels to group similar populations of cells holds great potential for 
future applications in machine learning approaches to register cells between studies, particularly in cases where 
biologically or clinically relevant populations of cells have been identified on multiple platforms where direct 
comparison of the data is not possible due to highly divergent ranges and scales. MEM also successfully 
distinguished populations of human immune cells from glioma cells even when common immune cell markers 
were left out of the analysis.  
Going forward, these methods can be adapted and applied for automated cell population discovery, 
tracking, and quantitative comparison. The modular nature of the computational analysis workflow presented 
here lends itself to adaptations for various experimental and clinical applications. For example, alternative 
dimensionality reduction methods like ISOMAP or LLE, described in Chapter 2, could be substituted for viSNE 
analysis for data expected to have show continuous, progressive phenotypes in contrast to the discrete 
populations found in samples like human blood. Alternative clustering or automated gating methods could also 
be substituted for SPADE. This overall workflow, which broadly entails quality control, comprehensive data 
visualization for major group identification, and automated subpopulation identification, can also be extrapolated 
to other data types, such gene expression and imaging data. Another key potential area of advancement for this 
workflow is increased automation for each step. Highly automated workflows will expedite analysis of large 
datasets and produce more robust and repeatable results. 
The method outlined in Chapter 3 for quantifying cellular phenotypic distance in a reduced-dimensional 
space establishes the conceptual framework for quantifying sample-level cellular heterogeneity. The concept 
presented here highlights the need for multi-variate, quantitative metrics of phenotypic heterogeneity. Tools like 
viSNE and SPADE provide informative qualitative representations of the data. However, quantitative approaches 
are needed to comprehensively compare sample-level heterogeneity and correlate this heterogeneity with 
clinical outcomes and biological mechanisms. When quantified, cellular heterogeneity has the potential to serve 
as a biomarker of disease prognosis, therapy response, and other clinical parameters. 
Advancements in cancer therapy rely on the development of novel methods for quantifying the features 
specific to clinically relevant populations of cells, for tracking those populations of cells over the course of therapy 
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and recovery, and comparing populations of cells from different patients, studies, and tissue sources. MEM 
analysis provides scaled enrichment scores in the form of labels that are comparable between platforms and 
robust against instrument variation. These labels can be used as quantitative descriptors for cell populations and 
compared across studies to automatically determine population identities. Going forward, a database could be 
created to store the MEM labels derived from established cell types against which newly identified populations 
can be compared. A machine learning algorithm could also be developed to improve cell classification as 
additional MEM labels were added to the database. Given a population of cells and set of measured features, 
the tool would calculate a MEM score for that population using either a user-defined population or a standardized 
cell population as reference. The resulting MEM scores could then be compared to the MEM labels of previously 
defined cell populations in the database, and probability or similarity scores would be returned estimating the 
most likely biological identity of the new population of cells. 
The methods described in this dissertation also have significant potential for clinical applications. As high 
dimensional analysis of clinical samples becomes routine, workflows such as that described in Chapter 2 will be 
needed to rapidly and automatically group cells into subpopulations and provide an interpretable visual output 
for clinical assessment. These types of tools may also be useful for identifying cellular features that correspond 
to clinical parameters, as demonstrated by the use of viSNE in Chapter 3 of this dissertation for quantifying a 
shift in AML blast phenotype that is seen in patients with negative outcomes. Tools that quantify cellular 
heterogeneity and feature enrichment therefore have the potential to provide novel biomarkers for disease 
prognosis. MEM analysis may also be useful for identifying features specifically enriched on clinically relevant 
populations of cells, specifically those resistant to therapy, and point to potential therapeutic targets against the 
resistant cell populations. 
As technological advancements lead to increasingly large datasets, novel computational tool 
development will be needed to extract meaningful and useful information from these data in order to continue 
improving disease treatment and gain a more complete understanding of human biology. 
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APPENDIX A 
 
 
 
USE OF VISNE ANALYSIS TO COMPARE METABOLISM OF CELL POPULATIONS 
Preface 
While the majority of my dissertation research focused on the analysis and interpretation of flow cytometry 
data, many other single-cell experimental platforms are available that provide valuable single-cell level 
information about biological samples. The ability to apply computational analysis tools and workflows to data 
generated across platforms will ultimately enable a more direct comparison of cells discovered using different 
methods. As a use case, I collaborated with Dr. Amy Shah, then a graduate student in Melissa Skala’s lab at 
Vanderbilt University, to apply computational analysis tools that were originally developed for flow cytometry data 
to single-cell imaging data. My goal was to use these tools to gain a comprehensive understanding of single-cell 
metabolic phenotypes of cells from a mouse model of head and neck cancer. To accomplish this, I linearly scaled 
the imaging parameters to a common 0-100 scale and then applied viSNE analysis to the scaled data in 
Cytobank (www.cytobank.org) to visualize the cells in a two-dimensional map according to their metabolic 
parameter similarities. My analysis ultimately confirmed that there was a greater degree of metabolic 
heterogeneity in the samples treated with chemotherapeutic drugs. Adapting tools like viSNE for use across 
experimental platforms will enable more efficient tracking of cell subsets identified from different tissues, studies, 
and platforms, thereby expanding  
The work presented here was originally published in Neoplasia 2015 (open access) (Shah, Diggins et al. 2015). 
http://www.neoplasia.com/article/S1476-5586(15)00143-8/abstract  
Introduction 
Cellular metabolism is altered in cancer cells, resulting in an abnormal ratio of cellular metabolites that 
can be experimentally measured. Two metabolic cofactors frequently used to determine the metabolic state of 
the cell, NAD(P)H and FAD, autofluorescence at measurable wavelengths and can therefore be imaged using 
high resolution autofluorescence imaging. The ratio of NAD(P)H and FAD fluorescence intensity, referred to as 
the optical redox ratio, is an established measure of cellular metabolism. In order to assess how two common 
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cancer drugs, cetuximab and cisplatin, affected cancer cell metabolism in a mouse model of head and neck 
squamous cell carcinoma, mice with FaDu tumors were treated with the compounds and the tumors were 
subsequently imaged to quantify the per-cell optical redox ratio. To visualize the heterogeneity in cellular 
metabolism, viSNE analysis was used to organize cells in a reduced-dimensional space according to imaging 
parameters. From these analyses, a greater degree of cellular metabolic heterogeneity was found in tumors 
treated with cetuximab and cisplatin compared to an untreated control.  
Methods 
Imaging analysis of mouse tumor was performed as described in Shah, et al (Shah, Diggins et al. 2015). 
The seven optical metabolic imaging parameters that were measured included NAD(P)H α1, NAD(P)H τ1, 
NAD(P)H τ2, FAD α2, FAD τ1, and FAD τ2. In order to compare the parameters, they were each transformed to a 
common scale from 0 to 100, with the highest value for each parameter being 100. The data were converted 
from Excel matrices to FCS files that could be uploaded to and analyzed using Cytobank (www.cytobank.org) 
for viSNE analysis. All seven of the scale-transformed parameters were used in the viSNE analysis. 
Results 
viSNE analysis of all seven measured optical metabolic imaging parameters revealed a population of 
cells from the cetuximab and treatment groups that was distinct from the cells of the control group (Figure A-1A). 
Visualization of heat intensity of the imaging parameters on the viSNE ap indicated that NAD(P)H τ1 and FAD τ1 
contributed the most variation to the mapping of the cells (Figure A-1B and C). The increased cellular 
heterogeneity seen in the treatment group by viSNE analysis was also seen in analysis of individual imaging 
parameters (Shah, Diggins et al. 2015).  
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Figure A-1. Single-cell analysis using the dimensionality-reduction technique viSNE reduced seven optical 
metabolic imaging parameters to two dimensions for visualization of heterogeneity across individual cells. To 
account for different scales between parameters, common linear transformation was applied within each parameter 
across all treatment groups so the transformed values ranged from 0 to 100. A) viSNE analysis shows a distinct 
population of cells for the control group. The cetuximab and cisplatin treatment groups overlap with the control group and 
also comprise a separate population of cells (B,C). Heat intensity indicates short fluorescence lifetime components (τ1) for 
(B) NAD(P)H and (C) FAD. 
Conclusions 
viSNE analysis was successfully applied to single-cell fluorescence imaging data to reveal the metabolic 
cellular heterogeneity that arose from cisplatin and cetuximab treatment of mice with FaDu tumors. 
Dimensionality reduction tools like viSNE can be used with single-cell data from non-flow cytometry platforms to 
inform on cellular heterogeneity and to identify distinct populations of cells. 
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